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STUDY OF ELECTRON TRANSFER THROUGH THE REDUCTASE DOMAIN
OF NEURONAL NITRIC OXIDE SYNTHASE AND DEVELOPMENT OF
BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS

YUE DAI

ABSTRACT

Crystal structure of neuronal Nitric Oxide Synthase reductase (nNOSr) implies
that large-scale domain motion is essential for electron transfer. However, the details are
not well understood. To address this, we generated a functioning “Cys-lite” version of
nNOSr and then replaced the nNOSr Glu816 and Arg1229 residues with Cys in the FMN
and FAD domains (CL5SS) in order to allow cross-domain disulfide bond formation
under pH 9 or to cross-linking using bis-maleimides. Cross-linked CL5SS exhibited a
≥95% decrease in cytochrome c reductase activity and reduction of the disulfide bond
restored the activities. The results demonstrate that a conformational equilibrium
involving FMN domains motion is essential for the electron transfer. A graded
lengthening of the bis-maleimide cross-linkers was associated with an increase in activity,
thus helping to define the distance constraints for domain opening. Stopped-flow kinetic
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studies showed cross-linking did not negatively affect the hydride transfer and interflavin electron but severally impaired the electron efflux from the FMN domain to its
redox partner. How these findings impact our understanding of the nNOS catalytic cycle
and details are discussed.
Staphylococcus aureus nitric oxide synthase (saNOS) helps S. aureus to maintain
its antibiotics resistance, making saNOS a drug target. However, in vitro determination of
saNOS inhibitor potency by activity assay is challenging because saNOS lacks an
attached reductase. Herein, we employ the following approaches to optimize the in vitro
assessment of NO synthesis by saNOS (1) B. subtillis flavodoxin YkuN and B. subtillis
flavodoxin reductase FLDR were adopted as reductase partners for saNOS; (2)
PEGylated-oxyhemoglobin was used for the direct capture of NO; (3) a 96-well plate
format was used to increase the assay throughput. Our results showed that PEGylation of
oxyHb minimizes the futile redox cycling within the flavoprotein and ensured effective
electron transfer from produced NO to oxyHb. Nitric oxide produced by saNOS and cell
cytosol was successfully detected by our assays. We also tested the inhibitory potency of
six compounds derived from trimethoprim. They were confirmed to be H4F competitor
with IC50 varying from 1 µM to 1 mM. The most potent inhibitor UCP111F26M is very
specific to saNOS. Details of this inhibitor are discussed.
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CHAPTER I
GENERAL INTRODUCTION

1.1 Nitric oxide

Nitric oxide (NO) is a colorless gaseous molecule under standard condition and
has been long known as air pollutant[1, 2]. Surprisingly, in mid-1980s, studies showed
this short-lived simple inorganic molecule could be endogenously produced and could act
as an endothelium relaxing factor (ERF), a cytotoxic agent triggering immune response
and a signaling molecule[2-10]. By that time the concept that an inorganic gas, which
penetrates membranes and regulates the function of other cells in human organism was
entirely new. This discovery was rewarded Nobel Prize for physiology and medicine in
1998 and that was just the beginning of the story about NO.
With several decades’ study of NO’s physiological roles, now we know that NO
is a signaling molecule activating soluble guanylyl cyclase (sGC), which is the primary
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NO receptor, by binding to its heme moiety[11-13]. The binding between sGC and NO
induces the production of the second messenger cyclic guanosine monophosphate
(cGMP) from guanosine triphosphate (GTP) and triggers downstream signaling cascades
[11, 13, 14]. Besides being a signaling molecule, NO is also capable of posttranslationally modifying proteins, DNA and lipids[4, 6, 15-17]. Although NO is an
important biological molecule, NO accumulation in cells rises the risk of reactive
nitrogen species (RNS) production and nitrosative stress, which is a pathological
condition causing detrimental effects to host cell including apoptosis, proliferation,
mutagenesis and invasiveness[2, 7, 15]. So the NO detoxification by reducing or
antioxidant chemicals in cell is essential for the cell homeostasis[17].

1.2 Nitric Oxide Synthase (NOS)

Although NO can be produced by cellular respiration, the majority of NO in cell
is produced by an enzyme called nitric oxide synthase (NOS)[3, 18]. NOS coverts Larginine (L-Arg) into L-citrulline and NO in a NADPH and (6R)-5,6,7,8tetrahydrobiopterin (H4B) dependent manner via the intermediate N-hydroxy-L-arginine
(NOHA)[3, 18, 19]. Three NOS isoforms have been identified in animals[18]. Neuronal
nitric oxide synthase (nNOS, NOS type I or NOS-I) is constitutively expressed in neurons
and produces nM level of NO as signaling molecule in the nervous system[20]. Inducible
nitric oxide synthase (iNOS, NOS type II or NOS-II) is expressed primarily in
macrophages upon pathogen recognition and produces μM level of NO as part of immune
response[21]. Endothelial nitric oxide synthase (eNOS, NOS type III or NOS-III) is
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generally expressed in endothelial cells constitutively producing μM level NO for
endothelial cell relaxation[22, 23]. The genes of these three different isoforms are located
on different chromosomes and they share a 51-57% amino acid homology[24]. Although
they differ in expression levels and catalytic activities, these three NOS isoforms share
general structural features and catalytic mechanism[18, 24].

1.3 Structure of NOS

NOSs are multidomain metalloenzymes[25, 26]. NOS is usually referred to
homodimer but in fact the active form of NOS is a tetramer consisted of two NOS
monomers and two calmodulin (CaM) monomers[26]. The active form of NOS also binds
a series of cofactors including nicotinamide adenine dinuleotide phosphate (NADPH/
NADP+), flavin adenine dinucleotide (FAD), flavin mono nucleotide (FMN), H4B and
iron protoporphyrin IX (heme) [26]. An NOS molecule contains an N-terminal oxygenase
domain (NOSoxy) and a C-terminal reductase domain (NOSr) [26]. They are covalently
linked by a peptide hinge, which contains a CaM/Ca2+ binding sequence[26, 27]. The
NOSoxy domain contains binding sites for heme, H4B and L-Arg[26]. The reductase
domain contains binding sites for NADPH, FAD and FMN[3, 26]. The separate domains
are catalytically active and has been successfully over-expressed and purified in a variety
of expression systems for structural and functional studies[28, 29].
Comparison of oxygenase domain of different isoforms shows that they have
almost identical catalytic sites except for the L-Arg binding site (Asp in iNOS and Asn in
eNOS)[3]. Generally, the NOSoxy is a heme protein with the heme iron axially
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coordinated to a proximal Cys [30-32]. This pentacoordination pattern of heme allows the
heme iron to axially coordinate an oxygen molecule [30-32]. The heme is buried
interiorly in the NOSoxy and anchored stably by van der Waals interaction with
surrounding hydrophobic residues [30-32]. The porphyrin ring in heme is also
sandwiched by a Trp and a Phe by stacking interaction [30-32]. Dimerization of NOSoxy
generates a cavity close to the dimer interface allowing diffusion of L-Arg and citrulline
[30-32]. The L-Arg binding site locates in the narrow part of the cavity [30-32]. Such
structure features make the guanidino group of L-Arg lay coplanar with heme and also
forms hydrogen bonds with surrounding residues [30-32]. NOHA binds the same way as
L-Arg with NOS [33]. The binding cavity of H4B is also located close to the dimer
interface [30-32]. The H4B interacts with NOSoxy primarily through stacking interaction
between the pterin ring and a surrounding Trp residue[30]. Hydrogen bonding networks
between H4B side chains and the N-terminal hook also helps to anchor H4B on its binding
site[30, 34]. Interestingly, a zinc finger has also been identified on the bottom of the
dimer interface and it is generally believed to be important for the NOS dimer
stability[30].
NOSr belongs to the dual-flavin reductase family and consisted of a covalently
attached FMN binding domain, a FAD binding domain and a NADPH binding domain
[35]. The FAD binding domain and NADPH binding domain together function as a
ferredoxin-NADP+ reductase (FNR) module and FMN module functions as ferredoxin
[35]. These domains are part of the electron transfer chain during NOS catalysis and the
details about electron transfer though NOSr are discussed in chapter II.
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1.4 NOS Catalysis

NOS is a unique enzyme that has attracted tremendous interest over decades due
to its high biological importance and chemical complexity. It uses flavins as electron
transfer component and heme as catalytic center, which distinguishes NOS from most of
other heme proteins[36]. The structural components of NOS co-operate to make NO
biosynthesis efficient and allow NOS to be specifically regulated by multiple regulatory
factors[35]. The intricate structure-function relationship of NOS is still one center topics
of NOS research.
The biosynthesis of NO by NOS has been studied extensively and the general
scheme of NO production by NOS is shown in Fig. 1[35]. Briefly, oxygen first oxidizes
the guanidine nitrogen on L-Arg, producing the stable intermediate NOHA that then
oxidizes NOHA, producing NO and L-citruline under the catalysis by NOS. Although the
scheme in Fig 1 looks straight forward, the stepwise electron transfer on heme center of
NOS is very complex (Fig. 2)[37]. NADPH first binds to NOS reductase domain and
transfer one electron to NOSr as hydride[37]. This electron is then transferred to the
ferric heme center in NOS oxygenase domain and reduces the ferric heme to ferrous
heme[37]. This allows oxygen to bind the ferrous iron center on heme to form a superoxy
species (species I) [37]. Species I is not reactive toward L-Arg but it can receive another
electron from H4B or NOSr (in absence of H4B) to form an intermediate heme-peroxo
species (species II)[37]. Species II can be further protonated and converted to a reactive
iron-oxo species (species III)[37]. Species III is capable of hydroxylating L-Arg into
NOHA or hydroxylating NOHA into citrulline and NO[37]. The produced NO is initially
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bounded to the ferric heme center and released afterwards[37]. In the overall biosynthesis
of NO, the reduction of ferric heme into ferrous heme is the slowest step[37]. The H4B
radical formed after H4B provide an electron to the heme center is recycled by
downstream reaction[37]. The electron must be transferred to NOSoxy at precise time
and rate to achieve optimal NO synthesis and to minimize the reactive oxygen species
formation[37]. Details about the reactivity of these related species have been discussed
[38].
Besides NO production, the NO release from heme-NO complex also limits the
NOS catalysis[37]. In one hand, the produced NO needs to get off the heme binding site
so the heme can bind another oxygen molecule to start another round of catalysis[37]. In
the other hand, the heme-NO complex can be oxidized and ultimately resulting in nitrate
formation without NO release[37]. The cycle that releases the NO is referred to as
“productive cycle” and the cycle in which the heme-NO complex is reduced into nitrite
without free NO production is referred to as the “futile cycle”[37]. The heme-NO
complex can also be reduced by NOSr and forms a ferrous-NO complex[37], which
releases NO at a very slow rate[37]. These processes together create a global mechanism
for NOS catalysis (Fig 3) and give a general idea about how both NO production and NO
release affect NOS biosynthesis [37].

Fig. 1. Scheme of NO production catalyzed by NOS from L-Arg
6

Fig. 2. L-Arg and NOHA oxidation on the heme center of NOSoxy. The
ferric heme receives an electron from NOSr and is reduced to ferrous heme.
The ferrous heme binds oxygen and forms a superoxy species I. Species I
receives another electron to form intermediate heme-peroxo species II, which
can be further convert to iron-oxo species III. Species III is capable of
hydroxylating both L-Arg and NOHA.
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Fig. 3. Global model of NO biosynthesis. The heme reduction rate (kr) is the
rate-limiting step of the NO biosynthesis by NOS. The kcat1 and kcat2 represent
the conversion rates of FeIIO2 species to FeIIINO species. The FeIIINO species
can either release NO with a rate kd or be reduced into FeIINO species with a rate
kr’. The FeIINO species can be oxidized by O2 and convert back to the ferric
heme with a rate kox.
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1.5 nNOS Physiology

nNOS, which can be expressed in immature and mature neurons, is responsible
for majority NO production in nervous system and exists in both particulate and soluble
forms [20]. However, studies show nNOS can also be expressed in rat cardiac myocytes
and rat brain blood vessels[39]. nNOS is either bond to plasma membrane directly or
indirectly anchored to the plasma membrane by adapter proteins to exert its function[20].
Adaptor proteins including post-synaptic density protein 93 (PSD93), post-synaptic
density protein 95 (PSD95), synapse associated protein 90 (SAP90) and CAPON
(carboxy-terminal PDZ ligand of nNOS) also help to delivery nNOS to its discrete
site[20]. Interestingly, many studies indicated that the PDZ domain of nNOS can interact
with a variety of proteins which also contain a PDZ domain and these interactions play a
regulatory role in nNOS distribution in cells and nNOS activity[20].
Function of nNOS-derived NO is concentration dependent. It is a physiological
neuromodulator mediating synaptic plasticity at low concentrations (nM), but a
neurotoxic factor at higher concentrations (M)[20]. NO produced by nNOS involves in
a variety of physiological and pathological conditions and several selected nNOS related
conditions are listed below.

1.5.1

Neurogenesis

Two major observations support the hypothesis that nNOS is related with
neurogenesis. First, subventricular zone (SVZ, a neurogenesis site) is surrounded by
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neurons, which contain nNOS[40, 41]. Second, neuronal precursors in dentate gyrus (DG,
another neurogenesis site) are capable of expressing nNOS [42]. Several studies have
been done trying to reveal the function of nNOS in neurogenesis. The majority of
publications in last ten years suggest an inhibitory role of nNOS in neurogenesis, but
excitatory effects are also been reported[20].
Previous studies imply that NO is related with neuronal tissue formation
processes and has antiporoliferative effects by inhibiting the epidermal growth factor
(EGF) receptor [20]. Studies show that NOS inhibitor N-nitro-L-arginine methyl ester
(L-NAME) increases the percentage of BrdU-immunoreactive cells, which is an
indication of cell proliferation, cultured in vitro in presence of EGF and NO donor
diethylenetriamine-nitric oxide adduct (DETA-NA) leads to a decrease in cell
proliferation in mouse SVZ cultured in vitro [43]. Mouse model studies show NOS
inhibition by 7-nitroindazole (7-NI) or nNOS gene knockout is capable of raising the
number of mitotic cells in SVZ and the olfactory bulb (OB, an olfactory related neural
structure). It also increases the number of progenitor cells in DG[44]. Moreover, it has
been showed that in mice model the number of cells generated in DG and olfactory
subependyma can be increased by both intracerebroventricular infusion of a NOS
inhibitor or nNOS gene knockout[44]. Although most evidences so far imply that nNOS
derived NO inhibits SVZ neurogensis, there are a few studies show that nNOS-derived
NO can promotes neurogensis in hippocampal[45]. The cause of such controversy still
remains unclear and requires further study.
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1.5.2

Memory and Learning

Both learning and memory are complicated multi-step processes[46]. Although
their mechanism is still not entirely clear, there are evidences showing that NO plays an
important role in these processes[47]. Previous animal model studies show that inhibition
of nNOS impairs hippocampal long-term potentiation, synaptic plasticity and long-term
memory formation[48, 49]. It has been shown that pharmacological inhibition of nNOS
by 7-NI, at the doses that do not affect blood pressure, could induce amnesic effects in
animals in both water maze and the a-arm radial maze[50]. The routes which animal was
treated by 7-NI also affect the experiment outcome, implying nNOS was involved in
different phase of memory[50]. Similarly, studies show that genetic inhibition of nNOS
caused by nNOS gene knockout impaired the cognitive performance and spatial memory
of mice[51]. Further study implies that nNOS gene removal induces an abnormal
expression of a series of exocytotic machinery-related proteins including glycolytic
enzymes and T-complex protein 1, resulting an impaired spatial memory [52]. Although
such observations show clear relationship between nNOS and memory/learning, details
about how nNOS regulates or affects these processes remain large unknown and require
further study.

1.5.3

Excitotoxicity and Ischemia

Studies have shown that nNOS is particularly related with excitotoxicity, which is
a pathological process resulting neuronal injury or death by an excessive synaptic release
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of neurotransmitter such as glutamate[53]. During excitotoxicity process, excitotoxins
binds their receptors such as N-methyl-D-aspartate receptor (NMDA) receptor and allows
Ca2+ influx into the neural cells, which activates a series of enzymes including NOS [5456]. Excitotoxicity breaks the homeostasis of neurons, damages the cell structures and
eventually cause cell death[55, 56]. Previous in vitro studies indicate that nNOS is one
major cause of NMDA neurotoxicity[55, 56]. In vitro experiments show primary cortical
neuronal cultures from nNOS null transgentic mice are more resistant to NMDA toxicity,
indicating NO produced by nNOS it one major source of neurotoxiciy [57].

1.5.4

Depression

Major Depressive disorder (MDD, clinical depression or unipolar depression) is a
chronic recurring and potential life threatening mental illness characterized by consistent
depressive mood and a loss of interest in normal relationship and activities[58]. World
Health Organization estimated that MDD would the primary cause of disability by
2020[58]. Although little is known about the exact mechanism of its pathophysiology,
research shows nNOS plays an important role in the pathogenesis of MDD [59, 60]. It
has been shown that plasma nitration concentration in depressed patients is significantly
elevated and commonly used antidepressant paroxetien and imipramine (IMI) are capable
of inhibiting NOS activity in animals and humans[60]. Studies also show that 7-NI (a
NOS inhibitor mentioned earlier) could induce antidepressant-like effect and this effect
could be reversed by L-Arg pretreatment but not D-Arg[61]. Study with chronic mild
stress (CMS) model also shows the importance of nNOS in pathophysiology of
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depression [62]. It has been shown that nNOS expression level is increased in
hypocampus with CMS and inhibition of nNOS could prevent CMS-induced
depression[62]. Similarly, nNOS gene knockout mice is also found to be resist to CMSinduced depression[62]. However, why nNOS could induce depression and whether
nNOS is a common target of antidepressants still requires further study.

1.5.5

Parkinson’s Disease

Parkinson’s disease (PD), featuring muscle rigidity, tremor, bradykinesia, changes
in speech and gait, is a central nervous system dysfunction mainly affecting the motor
system [63, 64]. It caused by progressive loss of dopamine-generating cells in the
substantia nigra[64]. The relation between PD and nNOS was studied using nNOS
knockout mice with a nNOS inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) [65]. MPTP is a drug that induces PD similar symptoms in both human and
rodents[65]. Comparing the behavior of nNOS knockout mice and wild type littermates
after treated with MPTP showed that nNOS knockout mice were more resistant to MPTP
neurotoxicity [65]. Moreover, study shows that 7-NI can protect wild type mice from
MPTP neurotoxicity, implying that nNOS is related with PD pathogenesis[66]. In the
meantime, increased level of nNOS expression, NO production and nitrated protein
amount were found in basal ganglia and circulating neutrophils of PD patients[67]. These
observations suggest that nNOS plays a role in the pathogenesis of Parkinson’s disease
but the details are still poorly understood and require further study.
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1.5.6

Alzheimer’s Disease

Alzheimer’s disease (AD,) is a chronic neurodegenerative disease featuring shortterm memory loss, mood swing, speaking and orientation problems and other behavioral
issues[68]. Symptoms get worse overtime and eventually lead to death within three to
nine year[68]. AD is associated with two critical processes in brain: neuritic plaque
formation

caused

by

amyloid

b-peptide

(Ab)

aggregation

and

tau

protein

hyperphosphorylation that leads to neurofibrillary tangles[68-70]. Previous study shows
chronic intracerebroventricular infusion of Ab1-40, an Ab isoforms, causes RNS
formation and protein nitration on their tyrosine[70]. Moreover, study shows nitrated
proteins in AD patient are highly co-localized with nNOS in cortical pyramidal cells,
implying the protein nitration is regulated through nNOS related processes[71, 72] . Also,
expression level of all three NOS isoforms is elevated in AD patients[72, 73]. These
observations suggest that NO and NOS plays important roles in AD. Study of the effect
of NO on AD and pathological details of NO and nNOS on AD would ultimately benefit
its treatment.

1.6 Bacterial Nitric Oxide Synthase History

The history of NO being a biological product begins at 1967, when NO was
identified as marine bacterium Pseudomonas perfectomarinus denitrification product[74].
Soon after that more bacteria including Thiobacillus denitrificans, Micrococcus
denitrificans and Paracoccus denitrificans were identified belonging to the
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denitirification bacteria family[75-77]. These bacteria utilize nitrite primarily for energy
generation with the help of a copper-containing nitrite reductase[25]. This process also
helps these bacteria balancing their redox state during the anaerobic respiration[25].
Although NO as biological compound was first identified in bacteria, whether
prokaryotes contain nitric oxide synthase remains controversy until late 1990s. With the
help of sequencing technology it has been identified that the open reading frame of
Bacillus subtilis encodes an mNOSoxy similar protein[78]. This protein conserves all the
key catalytic residues for NO synthesis, suggesting it is capable of producing NO from LArg[78]. Soon mNOSoxy similar proteins were identified in Deinococcus radiodurans by
genomic sequencing as well[79].
The enzymatic validation of these bacterial nitric oxide synthases (bNOS) started
in 2002. Adak. S et al. cloned the gene of the mNOS similar protein in Deinococcus
radiodurans (drNOS) into a bacterial protein expression vector and successfully
overexpressed and purified the drNOS from E. coli[80]. This drNOS is revealed to be a
stable homer dimer, containing heme and maintaining all the spectroscopic features of
mNOSoxy[80]. drNOS is capable of producing citrulline and nitrite from L-Arg in
presence of a nNOS reductase in a H4B dependent way with a rate much slower than
mNOS[80]. For the first time it has been shown that prokaryotes encode a protein, which
has NOS activity. Later, study on the NOS similar protein identified in Bacillus subtilis
(bsNOS) revealed the bsNOS is capable of producing NOHA and NO sequentially, which
is the same as mNOS[81]. Furthermore, both in vivo and in vitro studies prove that NO is
a bona fide produce of other bNOSs[82-86]. To date, bNOS has been identified in a few
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other bacteria species including Staphylococcus aureus, Bacillus anthrasis, Streptomyces
turgidiscabies and Geobacillus stearothermophilus [80-86].

1.7 Structure of Bacterial Nitric Oxide Synthase

Interest about bNOS structure had been raised immediately after the discovery of
bNOS. The first bNOS crystal structure was published in 2002 for bsNOS[87]. Its crystal
structure suggests that the bsNOS is highly structurally similar with mNOSoxy[87]. As
mNOXoxy, the bsNOS is a homer dimer and each monomer contains a heme and the
heme is buried deeply in a “catcher’s mitt” fold [87]. The heme of bsNOS is axially
coordinated with a Cys and interacts with Tyr325 by hydrogen bond and stack interaction
[87]. Similar to mNOS, the substrate and pterin binding sites of bsNOS locate on the
dimer interface[87]. However, bsNOS also notably differs from mNOSoxy in the ways
that bsNOS lacks the N-terminal hook and tetrahedral zinc finger, which is important for
H4B binding and H4B specificity[87]. More importantly, the bsNOS lacks the covalently
attached reductase domain, which implies it can only accept electrons from surrounding
electron donors and is not regulated by CaM[87]. Until now, crystal structures of several
other bNOS including gsNOS and saNOS has been resolved and they are all strongly
assemble the structure of bsNOS[88, 89]. Interestingly, there is a unique member in
bNOS family. The NOS similar protein in a gram-negative bacterium Sorangium
cellulosum (scNOS) has a covalently attached reductase module[90, 91]. Unlike the
mNOS, the reductase domain of scNOS is consisted of a Fe2S2 cluster rather than flavin

16

containing domains[91]. Also, the reductase domain of scNOS locates on the N-terminal
domain, which differs from the domain assemble pattern of mNOS[91].

1.8 Catalysis of Bacterial Nitric Oxide Synthase

NOS is one of the most substantially studied enzymes, this provides a solid
foundation of understanding bNOS catalysis[25]. From a structural point of view, the
catalytic center of bNOSs is almost identical to mNOS except that a conserved Val near
heme iron in mNOS is substituted by IIe[25]. Based on the structure similarities between
mNOS and bNOS, it is rational to predict that they have similar reactivity, which has
already proven by later studies[25]. Besides converting L-Arg or NOHA together with an
external reductase partner, bNOSs are capable of producing nitrate/nitrite from L-Arg in
presence of peroxide species with a rate similar to H4B free mNOS[25]. The catalytic
mechanism on the heme iron center in bNOS has been proven almost the same with
mNOS[25].
Such similarities between bNOS and mNOS imply that our knowledge about
mNOS catalytic mechanism can apply to bNOS and vice versa. This can be very useful
for NOS mechanism and kinetic studies since bNOSs offer several advantages. Many
identified bNOSs can be well expressed and readily purified from E. coli[25]. They can
form a stable dimer without pterin cofactors, which can be a simplification for
experiment design. The bNOS from special species allow us to study the NOS kinetics
under very different condition than mNOS. For example, we can study the kinetics of
NOS from thermophilic organisms under relatively high temperature. Moreover, their
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kinetics at ambient temperatures will be slow and that may help us to identify more
reaction intermediate.

1.9 Biological Functions of Bacterial Nitric Oxide Synthase

What bacterial NOS do has been one of the most intriguing questions ever since
the discovery of bNOS. It is obvious that the functions of bNOS significantly differ from
that of the mNOS since a single cell organism do not have a multi-cell immune system, a
nervous system or smooth muscle cells. By merging the findings of previous studies, it is
clear that functions of bNOS vary considerably depending on the species[25]. Here we
briefly summarized the functions of several bNOSs.

1.9.1

Streptomyces turgidiscabies NOS (stNOS)

The first function study on bNOS function came out on 2008 about Streptomyces
turgidiscabies nitric oxide synthase (stNOS). Streptomyces turgidiscabies is a bacterial
pathogen causing scab in potatoes[92]. stNOS is capable of producing NO in vivo,
confirmed by LC with chemiluminescence detection and in situ spin-trapping[83]. The
study was inspired by the discovery that the open reading frame of the stNOS gene is
located in a pathogenicity island, which confers thaxtomins (a class of plant toxin,
derived from cyclo-[L-tryptophanyl-L-phenylananyl] dipeptides) biosynthesis[93].
Moreover, the NOS gene also locates closely to two genes of nonribosomal peptide
synthases, which are involved directly in the thaxtomin biosynthesis[92]. The results of
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this study show 1) the thaxtomin production in S. turgidiscabies is sharply decreased by
NOS gene knockout; 2) the thaxtomin production in NOS knockout strains can be greatly
restored by NOS complementation and 3) the thaxtomin production can be inhibited by
mNOS inhibitors[92]. These results directly show stNOS relates with the virulence of
Streptomyces turgidiscabies via thaxtomins biosynthesis[92]. Surprisingly, result from a
15

N feeding experiment proves the NOS derived NO could nitrate the tryptophanyl

moiety of thaxtomins, which is very rarely seem in nature[92]. Taken together the fact
that NO relates with thaxtomin pathogenicity and NOS is the only known enzyme to
oxidize guanidinium group on Arg, it is clear that NOS is involved in the thaxtomin
pathogenicity by causing nitration of the thaxtomin Trp moiety[92]. Another interesting
finding is that S. turgidiscabies hyphae produces more NO than what is needed for toxin
biosynthesis in response to cellobiose (plant cell wall component) [92]. In the mean time,
NO is known as a signaling molecule stimulates plants growth and extension of root
tips[25]. That implies that stNOS is bi-functional. In one hand it facilitates the bacterial
infection, in the other hand it promote the growth of infected plant tissue[25].
However, several questions still remain unanswered. The function of nitration is
puzzling since thaxtomin itself is an active toxin without nitration. It is unlikely that the
thaxtomin get produced before it is nitrated because stNOS affect the production of
thaxtomin[25]. This implies that the nitration may affect the production of thaxtomin
precursor[25]. Also, so far biosynthetic nitration reaction directly by NO is still
unprecedented. Other enzyme(s) may be required for downstream enzymatic reactions
with NO to create more reactive nitrogen species such as nitrosonium (NO+) and
peroxynitrite (ONOO). Identities of such enzyme(s) and their role in NO oxidation still

19

remain unknown. Much more works are needed to understand the roles of stNOS in the
biosynthesis of thaxtomin[25].

1.9.2

Deinococcus radiodurans NOS (drNOS)

Deinococcus radiodurans is an extremophilic bacterium[94]. It is famous for its
resistance to several extreme environmental conditions including radiation, dehydration,
oxidative damage, coldness and even vacuum and known as one of world’s toughest
bacterium[94].
As one of the earliest identified bNOS, functions of drNOS have been studied
soon after its discovery by comparing the behaviors of wild type D. radiodurans and nos
gene deleted (Δnos) strain under different conditions[86, 94, 95]. Results show that
although Δnos strain only has a small growth defect in rich media, it is no longer able to
recover after UV radiation exposure[86]. Dramatic growth defect of Δnos strain under
UV radiation exposure has also been observed[86]. Moreover, providing exogenous NOS
by transformation a NOS expression plasmid or adding exogenous NO can complement
such growth defect of Δnos strain[86]. These facts clearly show that drNOS is a critical
factor for D. radiodurans survival under stressed conditions.
However, the mechanism of such protecting effect of drNOS is not entirely clear.
One proposed mechanism is that UV radiation induces drNOS expression, resulting in
production of NO[86]. The produced NO then acts as signaling molecule to upregulate
transcription of other growth factor, which is involved in cell proliferation[86]. Several
clues support such mechanism. First, NO addition triggers recovery of Δnos strain despite
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whether NO is added before, during or after UV exposure[86]. This shows NO does not
directly protect D. radiodurans from radiation damage, otherwise the cell would not
recover after the damage had already been done[86]. Second, previous studies show that
UV radiation can induce NOS expression of D. radioduran and the intracellular NO level
positively correlates with NOS expression level in D. radiodurans, which implies UV
radiation increases the intracellular NO level[86]. Third, transcriptional profiling
experiments reveal that UV radiation upregulates the gene expression of the general
growth regulator Obg in wild type D. radiodurans but not the Δnos construct[86].
Interestingly, although drNOS potentially involved in radiation resistance, Δnos strain is
still resistant to oxidative damage[86]. This implys the oxidative stress resistance of D.
radiodurans may be unrelated with NOS[86].
Similar to stNOS, drNOS is surprisingly involved in nitration of Tpr residues
[96]. Previous Pull-down experiments imply that drNOS interacts with a tryptophanyl
tRNA synthetase protein (TrpRS II), which is a tryptophanyl tRNA synthetases identified
in D. radiodurans[96]. TrpRS II is known for its ability to adenylate Trp and charging
tRNA Trp[25]. Study shows that drNOS interacts with TrpRS II and also destabilizes the
interaction between fluorescent ATP analogs and TrpRS II[25]. In the other hand, TrpRS
II increases the affinity between drNOS and Arg[25]. More importantly, drNOS is found
to catalyze formation of a small amount of 4-nitro-Trp alone together with a mammalian
reductase[25]. TrpRS II and ATP significantly increase the yield of 4-nitro-Trp while
H4B inhibits the production of 4-nitro-Trp[25]. This implies that drNOS and TrpRS II
may work together to produce 4-nitro-TrptRNATrp rather than producing NO [25]. The
produced 4-nitro-Trp tRNA may act as substrate for downstream reactions[25]. However,
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the reactivity, detailed mechanism and kinetics of drNOS and TrpRS II are still unclear.
Overall, many questions about drNOS still remains unanswered.

1.9.3

NOS in Bacillus anthracis, Bacillus subtilis and Staphylococcus aureus

Nudler group in NYU medical school has studied functions of NOSs in several
Bacillus and Staphylococcus strains by comparing the behavior of NOS gene deleted
strains (Δnos) with the wild type strains under a series of stressed conditions[97, 98].
Results show that 1) endogenous NO could be produced by the NOS in the tested
bacteria; 2) wild type strains are more resistant to ROS; 3) significant growth defect of
Δnos strain in presence of ROS was observed and such growth defect can be eased by
providing external NO or NO donor; 4) survival percentage of Δnos strains under high
dose of ROS can be greatly increased by exposing bacteria to NO for short time (5
seconds) before adding reactive oxygen species (ROS)[97]. These results clear show that
the NO protects these bacteria against oxidative stress[97]. Three mechanisms of such
protective effect of NO have also been proposed based on the results. (1) NO reacts
directly with ROS including acriflavine (ACR) and convert them into less toxic
reagents[97]. 2) NO suppresses the Fenton reactions (a reaction which generates
ROS)[97]. The reduced thiol in B. subtilis can reduce ferric iron thus promote Fenton
reactions[97]. NO is capable of interrupting the thioredoxin system thus blocking the
formation of free thiol to protect B. subtilis from oxidative damage[97]. 3) NO induces
the expression of superoxide dismutase (SOD), which can convert superoxide species
into oxygen and water thus protect B. subtilis[97].
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Such NO-mediated protection mechanism from ROS is important for pathogens to
infect their host since hosts often generate ROS to defend the infection[97]. Mouse model
studies show that spores of the nos gene deleted B. anthracis do not have virulence, and
its survival rate in response to macrophages is significantly lower than the wild[85].
These findings suggest that NO plays a complex role in the infections by bacterial
pathogens because NO protects bacterial pathogens and triggers host defense system at
the same time[25]. More insight of such paradox requires further study.

23

CHAPTER II
FMN DOMAIN MOTION IS ESSENTIAL FOR CATALYSIS OF NEURONAL
NITRIC OXIDE SYNTHASE

2.1 Introduction

2.1.1 Crystal Structure of nNOSr

Crystal structure of rat nNOSr has been resolved in 2004 by Garin et al. (Fig.
4.)[99]. It greatly improved our understanding about nNOSr structure and set up solid
basis for the structure-function study of nNOSr[99]. In the crystal structure, the nNOSr is
dimeric itself even without the oxygenase domain[99]. The flavin-containing face of
FMN domain is buried into the deep cup-shape surface formed by the FNR and an helical connecting domain (CD)[99]. The CD connects the FMN and FAD domain and
orients them in a conformation that their flavins align. In this conformation, the xylene
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ring methyl group of FMN is only 4.8 Å away from the xylene ring methyl group of
FAD, which makes the direct electron transfer between these flavins possible[99].
The FMN and FAD domain interact with each other in several ways[99]. They
interact directly through a double salt bridge located in the center of the FAD/FMN
domain interface formed by the residue pair Glu816 and Arg1229[99]. They also interact
through the hydrogen bonds, hydrophobic contacts and electrostatic interactions[29, 99].
The Autoinhibitory insert (AI) on the FMN domain inserts into the space between the
FMN domain and NADPH binding domain, which physically separates these two
domains[99]. Interestingly, the two resolved crystal structures that have been reported so
far exhibited a 4° rotation relative to each other, suggesting some flexibility of
nNOSr[99]. The weakly defined electron density on some parts of CD also implies the
conformational diversity of nNOSr [99].

Fig. 4. Crystal structure of nNOSr
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2.1.2 nNOSr Regulatory Elements

Previous studies reveal that nNOSr shares several common and unique regulation
elements with other dual flavin enzymes[35]. How these control elements function and
cooperate is a central topic in the area. Several control elements are listed below.

2.1.2.1 CaM Binding

CaM binding is a unique feature of NOS comparing to other flavin enzymes[35].
The CaM binding site locates upstream to FMN domain[99]. CaM binds to nNOS in
presence of Calcium boosts the electron transfer within the reductase domain[35, 100].
Previous studies imply CaM interacts with nNOS through nNOS Arg752-CaM Glu47
bridging interaction and such interaction triggers a conformational change on nNOSr and
removes the self-repression of nNOS[27]. More recently FRET study clear shows CaM
binding changes the distance distribution between FAD and FMN binding domains and
makes both FMN and FNR domains more dynamic[100].

2.1.2.2 Autoinhibitory Insert

Autoinhibitory insert (AI) amino acids locate within the FMN domain
sequence[99]. However, the crystal structure shows that the -helix of AI from residue
840 to 848 sequesters into the hydrophobic cave between FMN domain and NADPHbinding domain in the tertiary structure of nNOSr[99]. This structural element is believed
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to inhibit the electron transfer from FNR module to FMN module[99].

2.1.2.3 C-terminal Tail

C-terminal tail (CT) is another unique structural element of NOS. The crystal
structure of nNOSr indicates the CT contains an ordered -helix structure(residues 1401–
1412) and an unstructured part, which is invisible in the crystal structure[99]. The
ordered part of CT inserts into the FAD/FMN domain interface and shielding both FAD
and FMN from solvent, suggesting a regulatory role of CT[99]. CT hydrogen bonds with
residue Tyr899 on FMN and Asp1351 on the FAD domain respectively[99]. It also has
ionic interaction with NADPH and hydrophobic interactions with surrounding
hydrophobic residues on FAD and FMN domain[99]. Kinetic studies on CT truncated
nNOS proteins proved that the -helix of CT represses the electron transfer through
nNOSr and it also inhibits the NADP+ releasing [101, 102]. In comparison, the
unstructured part on CT has little effect on the activity of nNOSr and only a small effect
on the NPADH-binding[101].

2.1.2.4 Other Key Residues

Phosphorylation and residue Ser1412
Ser1412 in rat nNOS is an Akt-dependent phosphorylation site[103]. The crystal
structure of nNOSr showed Ser1412 locates on the end of CT[103]. The oxygen atom in
Ser1412, which forms a phosphate bond after phosphorylation, points directly towards
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the negative charged Glu916 and Asp918 on the FMN domain[103]. This suggests
phosphorylation on this site would induce an electrostatic repulsion between CT and
FMN thus may change the overall conformation of nNOSr[103]. Kinetics study on
S1412D nNOSr proves a negative charge on residue 1412 does fasten the electron
transfer through nNOSr and suggests such activation is conformation related[103].

FAD shielding residue F1395
The Phe1395 locates upstream to the CT and stacks with the isoalloxazine ring of
FAD in the nNOSr crystal structure[104]. Following kinetics studies on F1395S of
nNOSr reveal important regulatory roles of F1395 for nNOSr electron transfer and
catalysis[104]. F1395 weakens the interaction between NADP+ with nNOSr thus
facilitate NADP+ releasing to allow nNOSr bind NADPH[104]. More importantly, it
relates with the conformational equilibrium involving the FMN domain, which is likely
to be controlled by NADP(H) binding[104].

Hydride transfer and residue D1393
D1393 is a widely conserved residue among NOS[105]. In the crystal structure of
nNOS, the carboxyl group of D1393 is direct on top of the isoalloxazine ring of FAD and
it is thought to regulate the hydride transfer from NADPH to FAD[105, 106]. Kinetics
studies show mutation on D1393 significantly slows hydride transfer, implying D1393
facilitates the hydride transfer from NADPH to FAD[105]. However, the mechanism of
this excitatory effect of D1393 remains unclear.
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2.1.3 nNOSr Conformational Model

Crystal structure of nNOSr shows the isoalloxazine rings of FAD and FMN
cofactors are close enough for direct electron transfer[99]. However, the FMN cofactor is
deeply buried within the cave generated by FAD domain and CD, preventing electron
transfer from FMN to its redox partners[99]. The structure assemble study with NOSoxy,
NOSred modules and a CaM-NOS-peptide complex implies the shortest distance between
the FMN and heme cofactor is approximately 70 Å, which is too long for direct electron
transfer[36, 99]. At the meantime, kinetics study of nNOS suggested that nNOS exists in
different conformations during its catalysis[35, 100].
Based on these studies, we proposed a three-state, two-equilibrium model
describing the electron transfer mechanism on NOS (Fig.5)[35]. In this model, the entire
FMN domain swings back forth between FNR domain and NOS oxy, shuttling electrons
between these two domains[35]. The NADPH-derived electron transfer from FNR
domain to FMN domain in the equilibrium KA, which is the equilibrium between FNRFMN domain attached conformation (defined as “closed” or “FAD-shielded” form) and
the FNR-FMN domain unattached conformation (defined as “open” form)[35]. The
electrons transfer to NOSoxy in equilibrium KB. Such large-scale movement of FMN
domain has already been identified in the catalysis of other dual flavin enzymes including
methionine synthase and CPR[107, 108].

Fig. 5. NOS conformational equilibrium model
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2.1.4 nNOSr Electron Transfer Model

Flavins are cofactors for a variety of enzymes including NOS and they can act as
part of their electron transfer chain[36]. Flavins have three different oxidation states, fully
oxidized, semiquinone(sq) and hydroguinone(hq) as shown in Fig 6[109]. In the electron
transfer through nNOSr, only the hydroguinone(hq) is capable of donating electrons to an
acceptor since nNOSr thermodynamically stabilizes the semiquinone[109]. During
catalysis by nNOSr, FADhq donates an electron to FMNsq to produce FMNhq[109]. The
FMNhq can donate one electron to an electron acceptor[109]. The overall electron flux
pathway is shown in Fig 7[35].
Although Fig 6 looks quite straight forward, the actually electron transfer
mechanism may be complicated because the electron transfer happens simultaneously
with conformational motion in nNOSr and it is likely the electron transfer is regulated by
such conformational motions[35]. Based on our current understanding of nNOSr, we
proposed a simplified four state model to describe how conformational motions affect the
electron transfer through nNOSr (Fig. 8)[35, 109]. This model includes a conformational
opening equilibrium that allows FMNhq to donate one electron to its substrate and a
conformational closing equilibrium that allows FMNsq to receive one electron from
FADhq.
Here we define Ksq = k−1 / k1 and Khq = k−3 / k3 so that higher K values reflect a
higher percentage of nNOSr in open conformations[109]. This model has been used to
compute the cytochrome c reduction results of nNOS, eNOS, cytochrome P450 reductase
and methionine synthase reductase[109].
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Fig. 6. Oxidation state of FAD and FMN. Oxidized FAD or FMN receives one electron
through hydride transfer and becomes into a semiquinone radical, which can further
accept another electron and becomes into hydroquinone.

Fig. 7. Electron transfer path of NOS. NADPH donates one electron to FAD as
hydride. The electron is then transferred to FMN and finial to the oxygenase domain on
the other NOS monomer.
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Fig. 8. Electron transfer model of NOS reductase. In this model, k1 and k3 represent the
association rate of FNR and FMN. Similarly, k-1 and k-3 represent the dissociation rate of
FNR and FMN. The rate k2 is the FMNsq reduction rate. The rate k4 is the cytochrome c
reduction rate.

2.1.5 Conformation Study of a Mutated Cytochrome P450 Reductase

Cytochrome P450 reductase (CYPOR) is a related dual flavin enzyme that has an
attached FMN binding domain and a FAD binding domain[108]. It has been proposed
that its FMN binding domain undergoes large-scale movement during its catalysis[108].
And recent studies of CYPOR using biophysical and kinetic tools successfully proved
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this hypothesis[108]. The CYPOR mutant CYPOR N147C R514C is one of the key
components for these studies[108].
Similar to nNOSr, crystal structure of wild type CYPOR reveals a salt bridge
between its FAD binding domain and FMN binding domain between the residue Asp147
and Arg514[108]. The authors first engineered a CYPOR mutant having C136A, C228A,
C363T, C445L and C472T point mutations to delete the nonessential cysteine residues on
CYPOR[108]. They then engineered a disulfide bond between the FMN and FAD
binding domains of this CYPOR mutant by introducing the D147C and the R514C
mutations. This mutant is referred to as CYPOR 147CC514[108]. The disulfide bond
presumably prevents the movement of the FMN domain and was therefore expected to
drastically change the electron transfer and catalysis of CYPOR[108]. The crystal
structure of CYPOR 147CC514 revealed that the engineered disulfide bond successfully
cross-linked the FAD and FMN domains[108]. The cross-linked enzyme exhibited a
significantly lower steady-state activity and electron transfer rate from FMN to its redox
partners[108]. Breaking the disulfide bond in CYPOR 147CC514 with DTT restored its
normal catalytic activity[108]. These results directly showed that the FMN domain of
CYPOR is involved in a conformational equilibrium, that is essential for catalysis[108].
Unrelated NMR and small-angle x-ray scattering studies on CYPOR revealed that the
oxidized CYPOR does have open and closed conformations in solution and the ratio of
open and closed conformations in solution is approximately 1:1[107].
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2.1.6 Aims

Based on previous studies that suggest electron transfer through nNOSr is
conformationally regulated and inspired by the above studies of cross-linked CYPOR, we
created and utilized similar variants of the nNOSr protein (Cys-lite nNOSr and lockeddown nNOSr) that allow us to specifically link different domains by disulfide bonds and
by chemical crosslinkers. That allowed us to study the importance of domain motions on
nNOSr electron transfer and to test if FMN domain motion is essential for nNOSr
electron transfer.

2.2 Experiments

2.2.1 Reagents and Materials

Bis(maleimide)ethane (BMOE), bis(maleimide)butane (BMB), Bis(maleimide)hexane (BMH), bis(maleimide)diethylene glycol (BM(PEG)2), bis(maleimide)triethylene
glycol, (BM(PEG)3) were purchased from Thermo. Bis-Mal-PEG6 (BM(PEG)6) and BisMal-PEG11 (BM(PEG)11) were purchased from BROADPHARM. All other reagents and
materials were obtained from sources reported elsewhere[109, 110].
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2.2.2 Molecular Biology

pCWori vector containing rat nNOSr DNA was constructed by previous lab
members[109]. Rat nNOSr DNA with S774C, S823C, S921C, S945C and S1275C
mutations was made and subcloned into pCWori vector (Custom DNA Constructs, OH,
US). This mutant is called cys-lite nNOSr or CL5 since it has 5 Cys to Ser mutation. CL5
nNOSr DNA with E816C and R1229C mutations was also made and subcloned into
pCWori vector (Custom DNA Constructs, OH, US). This mutant is referred to as CL5-SS.
Sequences of all mutant DNA were confirmed by Cleveland Clinic sequencing facilities.

2.2.3 Expression and Purification of wild type and mutant nNOSr

pCWori vector containing DNA of wild type or mutant nNOSr were each
transformed in to E. coli stand BL21 (DE3) for over-expression[110]. Transformed E.
coli cells were inoculated in 500 mL LB media at 37°C in the presence of 100 mg/mL
ampicillin with vigorous shaking (250 rpm) overnight. Eight 2 L flasks each containing
50 mL of overnight culture, 450 mL TB and the same antibiotics were used for nNOSr
expression. The cultures were grown at 37 °C with vigorous shaking. 1 mM isopropyl-D-thiogalactopyranoside (IPTG) was added to induce nNOSr expression when the
cultures OD600 reached 0.8~1.0. Cultures were then transferred to room temperature and
grown for another 48 hrs with vigorous shaking (250 rpm). The cells were harvested by
centrifuging at 5000 rpm for 30 min. The cell pellets were resuspended with minimum
volume of 40 mM Epps, 150 mM NaCl, 10% glycerol, pH 7.6 containing protease
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inhibitors, phenylmethanesulfonylfluoride (PMSF) and lysosome. The resuspended cells
were sonicated using a Branson digital sonifier (3 × 35 s bursts on 35% power,
interspaced by 1min) on ice. All of the following procedures were done at 4 °C unless
indicated specifically. The lysates were centrifuged at 13000 rpm for 1 hr and the clear
supernatant was loaded onto a gravity 2’5’ ADP-sepharose column pre-equilibrated with
40 mM Epps, 150 mM NaCl, 10% glycerol, pH 7.6. The column was washed with 200 ml
of 40 mM Epps, 500 mM NaCl, 10% glycerol, pH 7.6 containing 1 mM EDTA and
eluted with 40 ml of 40 mM Epps, 150 mM NaCl, 10% glycerol, pH 7.6 containing 1
mM NADPH and 3 mM 2’(3’)-AMP. CaCl2 was added to make its final concentration 2
mM in the elute. The elute was loaded onto a CaM-sepharose affinity column preequilibrated with 40 mM Epps, 150 mM NaCl, 10% glycerol, pH 7.6 containing 1 mM
CaCl2. The column was washed with 100 ml of 150 mM NaCl, 10% glycerol, pH 7.6
containing 1 mM CaCl2 and the bound nNOSr protein was eluted with 50 ml of 150 mM
NaCl, 10% glycerol, pH 7.6 containing 3 mM EDTA. Eluted nNOSr was concentrated
using a 50 ml Millipore concentration unit with 50 kD cut off (EMD Millipore, MA).
Concentrated nNOSr wild type was dialyzed in 40 mM Epps, 150 mM NaCl, 10%
glycerol, pH 7.6 with 1 mM DTT. nNOSr CL5 and CL5SS were dialyzed in 40 mM Epps,
150 mM NaCl, 10% glycerol, pH 7.6. Protein was aliquoted and stored in -70°C.
Concentration of nNOSr and mutants were determined using an extinction coefficient of
22.9 mM-1 cm-1 at 457 nm[111].
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2.2.4 Preparation of Bis-maleimide Cross-linked nNOSr
10 mM Bis-maleimide cross-linker (BM) stock solutions were made in DMSO
immediately before use. Scheme of maleimide conjugation is shown in Fig. 9. BM crosslinking was carried out on ice by incubating protein pre-treated with 10 equivalents of
TCEP and 5 equivalents of NADP+ with 2 equivalents of BM for 40 min on ice in 40 mM
EPPS, 150 mM NaCl, 10% glycerol pH 7.0 buffer. The reaction mixture was further
incubated with Glutathione sepharose 4B resin (GSH resion) for another 40 min on ice to
remove any double BM reacted CL5SS as shown in Fig. 10. The reaction mixture was
centrifuged at 10000 rpm for 3 min at 4°C to remove the beads and the supernatant was
loaded onto a desalting PD10 column (GE healthcare Lifescience) to remove excessed
TCEP, NADP+ and BMs.
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Fig.9. Scheme of maleimide conjugation with thiol group and structure of
selected cross-linkers. The thiol group conjugates with the maleimide group on
the carbon-carbon double bond.
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Fig. 10. Side reaction of cross-linking and separation by GSH-resin. The bismaleimide cross-linking reaction with excess of cross-linker results in a mixture of
cross-linked protein and uncross-linked protein. The uncross-linked protein can be
pulled down by GSH resin, leaving only the cross-linked protein in the reaction
solution.
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2.2.5 Preparation of N-ethylmaleimide Conjugated CL5SS, Dithoreitol Reduced
CL5SS and pH 9 Treated CL5SS

20 mM N-ethylmaleimide (NEM) stock solution was made in ultrapure water
immediately before use. NEM conjugation was carried out at room temperature by
incubating protein pre-treated with 10 equivalents of TCEP and 5 equivalents of NADP+
with 10 equivalents of NEM for 1 hr in 40 mM EPPS, 150 mM NaCl, 10% glycerol pH
7.0 buffer. The reaction was stopped by passing the reaction mixture through a desalting
PD10 column (GE healthcare Lifescience). Dithoreitol (DTT) reduced CL5SS was
prepared by incubating CL5SS in 40 mM EPPS, 150 mM NaCl, 10% glycerol, pH 7.6
buffer containing 0.5 mM DTT for 1 hr on ice. The pH 9 treated CL5SS was prepared by
incubating CL5SS in 50 mM Tris-HCl, 150 mM NaCl, pH 9.0 buffer for 1 hr on ice then
passing a PD10 desalting column.

2.2.6 UV-Vis Spectroscopy

UV-Vis spectra of nNOSr wild type and mutants ranging from 250 nm to 700 nm
before or after cross-linking were obtained in 40 mM Epps, 150 mM NaCl, 10% glycerol
pH 7.6 using a Shimadzu UV-2401 PC UV-Vis spectrophotometer.
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2.2.7 Reactive Thiol Group Quantification

The number of remaining thiol groups on BM cross-linked CL5SS (CL5SS-BMs)
or CL5 was quantified using the Alexa Fluor 555 maleimide dye (A555, Thermo).
CL5SS-BMs were incubated with 1 equivalent A555 at room temperature for 10 min.
The reaction mixture was further incubated with CaM-sepharose affinity resin and 1 mM
CaCl2 for another 10 min at 4 °C. The CaM resin was then washed with 40 mM Epps,
150 mM NaCl, 1 mM CaCl2, 10% glycerol, pH 7.6 containing 1 mM CaCl2 until no
apparent absorption at 555 nm was detected in the wash buffer by the UV-Vis
spectrophotometer. The bound CL5SS-BMs was eluted using 40 mM Epps, 150 mM
NaCl, 10% glycerol, pH 7.6 with 2 mM EDTA. Concentration of nNOSr and mutants
were determined using an extinction coefficient 22.9 mM-1 cm-1 at 457 nm[111].
Concentration of A555 bound on the protein was determined using an extinction
coefficient 150.0 mM-1 cm-1 at 555 nm.

2.2.8 Reactive Mal Group Quantification

The number of maleimide groups remaining in the CL5SS- BM was quantified
using Amplite Flourimetric Maleimide Quantitation Kit (AAT Bioquest, CA) with a
standard curve obtained with NEM standards provided in the kit.
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2.2.9 Steady-state Cytochrome C Reductase Activity

Cytochrome c is a universal electron acceptor for dual flavin reductases[109].
Reduction of the cytochrome c by dual flavin reductase can be much faster than electron
transfer through the reductase, thus it not typically the rate limiting step[109]. The
steady-state cytochrome c reductase activity is widely used as an indication of enzyme
activity[109]. In this assay, a reaction mixture containing ~10 nM nNOSr proteins, 100
μM cytochrome c, 40 mM EPPS, 150 mM NaCl and 10% glycerol, pH 7.6 with 1 mM
EDTA or 100 μM CaM and 1 mM CaCl2 was placed in a cuvette. The reactions were
initiated by adding 100 μM NADPH. Absorbance at 550 nm versus time was record by a
UV-Vis spectrophotometer (Shimadzu UV2401PC) and the slope was calculated by the
built-in program of Shimadzu spectrophotometer software UVProble 2.32. The pseudozero order rate constant was calculated by dividing the slope value by the extinction
coefficient of 21 mM-1 cm-1[111]. The steady-state turnover number (kcat) was calculated
by dividing the pseudo-first order rate constant by the concentration of enzyme used in
the assay. Experiments were done at room temperature or 10°C and performed in
triplicate. The results were shown as mean ± standard deviation.

2.2.10 Flavin Reduction Kinetics

Full oxidized nNOSr proteins (10~15 M nNOSr protein in 40 mM Epps, 150
mM NaCl, 10% glycerol, pH 7.6, with 1 mM EDTA or 1 mM CaCl2, 30 M CaM and an
NADPH solution (100 M in 40 mM Epps, 150 mM NaCl, 10% glycerol, pH 7.6) were
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made anaerobic by alternatively applying negative pressure created by a vacuum pump
and nitrogen gas to sample solutions in an anaerobic cuvette for 90 min on ice. Anaerobic
samples were transferred to two syringes in Stopped-flow camber, which was made
oxygen free by flushing with nitrogen gas as shown in Fig. 11. (copied form TgK
website). Measurements were initiated by rapidly mixing 100 l solution from each
syringe in the by Stopped-flow instrument at 10 °C. The full spectrum in the range 400
nm to 700 nm and the absorbance change at 457 nm or 600nm were recorded by SF61DX2 or SF-61. The maximum absorbance value at 457 nm for individual nNOSr
protein was obtained by mixing the protein sample with 40 mM Epps, 150 mM NaCl, 10%
glycerol pH 7.6 buffer (no NADPH) in stopped-flow instrument. The minimum
absorbance value at 457 nm was obtained by mixing buffer (40 mM Epps, 150 mM NaCl,
10% glycerol pH 7.6) with the same buffer in stopped-flow instrument.

Fig. 11. Stopped-flow instrument setup
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2.2.11 Data Analysis of Flavin Reduction Kinetic Traces

The signal to noise ratio of flavin reduction time course was improved by
averaging 8-10 individual scans. A double exponential equation was used to fit the
recorded traces at 457 nm to get the rate constants using OriginLab 8.0 (OriginLab Co.
MA) with the constraint that the phase ratio of first and second phase is 1:1. This
constraint was applied because in the end of flavin reduction both FAD and FMN are
reduced and they contribute equally to the absorbance change at 457 nm[111]. A double
exponential equation was also used to fit the recorded traces at 600 nm to get the rate
constants. Percentage absorbance changes were determined using the maximum and
minimum absorbance value at 457 nm as 100% and 0%.

2.2.12 Pre-steady-state Cytochrome C Reduction Kinetics

A solution containing 10~15 M nNOSr protein and 1 mM EDTA in 40 mM
Epps, 150 mM NaCl, 10% glycerol, pH 7.6 was made anaerobic by alternatively applying
negative pressure created by a vacuum pump and nitrogen gas to sample solutions in an
anaerobic cuvette for 90 min on ice. The concentration of nNOSr proteins was
determined using an extinction coefficient 22.9 mM-1 cm-1 at 457 nm[111]. This solution
was first reduced by adding 200 M anaerobic NADPH then fully photo reduced by
adding 1 M 5-deazariboflavin then irradiating using a slide projector bulb until no
further decrease in UV-Vis absorbance was observed with further irradiation. A solution
containing 100 M cytochrome c was made anaerobic with the same procedures. The
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anaerobic samples were transferred to two syringes in stopped-flow instrument then
rapidly mixed at 10 °C. Absorbance change at 550 nm was monitored. Initial cytochrome
c absorbance at 550 nm (A550, Initial) was obtained by rapidly mixing the same cytochrome
c solution with an anaerobic buffer containing 40 mM Epps, 150 mM NaCl, 10%
glycerol, 200 M NADPH, pH 7.6 in the stopped-flow instrument.

2.2.13 Data Analysis of Pre-steady-state Cytochrome C Reduction Traces

The absorbance at 550 nm when 1 equivalent cytochrome c was reduced (A550,
Final)

by nNOSr was determined by using the equation:
A550, Final = A550, Initial +   L  [nNOSr]  0.5
Unit of nNOSr protein concentration is M in this equation.  is the extinction

coefficient of cytochrome c at 550 nm, which is 21 M-1 cm-1[111]. L is the path length
of SF51 Stopped-flow instrument, which is 1 cm. 0.5 was used because same volume of
nNOSr protein and cytochrome were mixed in the stopped-flow instrument. The time it
took to achieve 1 equivalent cytochrome c reduction was obtained by correlated A500, Final
with time in the absorbance trace monitored at 550 nm. The zero time absorbance at 550
nm recorded when mixing fully reduced nNOSr protein with cytochrome c is written as
A550. In this case, the Khq of nNOSr proteins, which represents the ratio of the open
conformation and closed conformation, is approximately equal to (A550 - A550,
( A550, final - A550) [111].
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initial)

:

2.2.14 NADP+ Titration

NADP+ binds nNOS and forms a charge transfer complex with the FAD
isoalloxazine ring, which results in a shift on its UV-Vis spectrum[104]. The spectrum of
20 M nNOSr proteins before and after adding 100 M NADP+ were recorded by a
Shimdazu UV-2401PC UV-Vis spectrophotometer and subtracted to obtain the spectral
shift. In a separate experiment, 20 M nNOSr proteins were titrated with aliquots of
NADP+ at room temperature. The spectrum after every titration point was recorded 3 min
after NADP+ was added. Absorbance difference between 510 nm and 457 nm from the
spectral shift was plotted versus NADP+ concentration.

2.2.15 Fluorescence Spectroscopy

Bound flavins in NOS have intrinsic fluorescence mostly due to the FMN[112].
Flavin fluorescence of nNOSr, CL5 and CL5SS-BMOE was measured in a 1 ml quartz
cuvette with 1 cm path length by a Hitachi model F-2500 spectrofluorometer. 2 M
nNOSr proteins in 40 mM Epps, pH 7.6 containing 3 M CaM and 0.6 mM EDTA were
used in this experiment. The emission intensity at 530 nm excited by irradiation at 457
nm was monitored versus time before or after adding 1 mM CaCl2 and 3 mM EDTA.
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2.3 Results and Discussion

2.3.1 Generation and Characterization of CL5 and CL5SS

The wild type nNOSr has 10 cysteine residues at position 744, 823, 921, 945,
1088, 1211, 1226, 1244, 1275,1284 and 1349[99]. Prior to engineering a Cys pair on the
FMN-FAD interface, it is necessary to remove all other the reactive Cys on nNOSr.
Previous Mass spec analysis of A555 labeled wild type identified 5 reactive Cys at
position 744, 823, 921, 945 and 1275 (data not shown). They are not in the regulatory
regions of nNOSr so they were changed to Ser. This nNOSr variant is referred to as CL5.
E816 and R1229 were selected for FAD/FMN domain cross-linking for two
reasons. First, these two residues naturally form a salt bridge between the FAD and FMN
domain, implying they are sterically suitable for cross-linking. Second, variant nNOSr
with single mutations on E816 or R1228 have been studied previously[113, 114]. The
results imply both E816 and R1229 are involved in the FMN domain-related
conformational equilibrium. These data also help to predict the impacts of the E816CR1226C double mutations on nNOSr function. The CL5 nNOSr with E816C R1229C
double mutation is referred as locked-down nNOSr or CL5SS.
During the purification process we found both CL5 and CL5SS maintained a
normal level of expression. The spectrum of CL5 almost overlaps with the spectrum of
wild type nNOS, indicating normal flavin content and flavin environment in CL5 (Fig.
12). Fig 12 also shows that CL5 did not react with A555 dye, confirming it did not have

47

any remaining dye-reactive Cys. This result agrees well with our mass-spec analysis that
identified reactive Cys groups.

Fig. 12. Spectra of nNOSr, CL5 and CL5SS

2.3.2 Validation of Cross-linking of CL5SS

The direct cross-linking reaction of CL5SS by BMs generates side products
including uncross-linked CL5SS with 2 bismaleimde groups on one CL5SS molecule as
shown in Fig. 9. In order to get rid of such side products, a further separation step using
GSH-sepharose to pull out the un-cross-linked nNOSr proteins was applied. To validate
our cross-linking method, the percentage of free thiol groups and maleimide groups on
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CL5SS cross-linked by BMs (CL5SS-BMs) was quantified. Fig. 13 indicates that < 5%
reactive thiol groups remained on all CL5SS-BMs after final processing. CL5SS also had
a very similar spectrum with wild type nNOSr, showing CL5SS has normal flavin
content. After breaking all the disulfide bonds in CL5SS by incubation with TCEP, every
CL5SS molecule had two reactive thiol groups. Also, the fluorescence intensities of 10
µM of CL5SS-BMs were lower than the most diluted dilute NEM standard (0.1µM),
making it impossible to quantify the remaining maleimide on CL5SS-BMs. We can only
estimate the remaining maleimide was less than 0.01 mol / mol nNOSr. These results
show our protocol is robust and capable of generating nearly pure sample of cross-linked
CL5SS.
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Fig. 13. Normalized spectra of CL5SS-BMs after incubation with A555. CL5SS-BMs
were reacted with A555 dye and their spectra were compared with wild type nNOSr
(negative control), CL5 (negative control) are CL5SS-A555 (positive control).

2.3.3 Steady-state Cytochrome C Activity of Cross-linked and DTT Treated CL5SS

Fig 14A shows CL5 has 84% of the activity compared to wild type nNOSr in
presence of CaM, and has a 3 times elevated activity compared to wild type nNOSr in
absence of CaM. This indicates the 5 Cys-Ser mutations do not impair the electron
transfer though CaM-bounded nNOSr. The elevated activity under CaM-free state is
commonly found in nNOSr variants with mutation(s) on its FMN or FNR surface[115]. It
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is generally believed that such mutations partially remove the self-repression by altering
the nNOSr conformation[114, 115]. The fact that relatively minor activity changes were
found on CL5 compared to wild type nNOSr indicates that CL5 is a suitable template to
engineer the locked-down nNOSr.
Cross-linking the FNR and FMN domains allow us to directly study the impact of
FMN domain movement. Figure 14B and 14C shows the activity of disulfide bond crosslinked CL5SS before and after DTT treatment and BMOE cross-linked CL5SS. The
results show that cross-linking of nNOSr on its FMN and FNR domain by both disulfide
bond and BMOE results in a significant decrease of its cytochrome c reductase activity.
Moreover, breaking the disulfide bond restored the activity of the disulfide bond crosslinked CL5SS. However, this data did not totally rule out the possibility that it was the
nonspecific thiol group oxidation or the thiol maleimide modification, rather than the
cross-linking itself, that caused such activity decrease. In order to test this, we examined
the activity of two negative control groups under the same conditions. Negative control I
was CL5 treated the same as CL5SS. CL5 does not have any reactive Cys thus cannot be
cross-linked. This control can determine if the nonspecific thiol group oxidation would
inhibit the nNOSr activity. Negative control II was an NEM reacted CL5SS. NEM is a
mono-functional maleimide. It is capable of reacting with CL5SS but it cannot cross-link
FMN domain with FNR domain. This control can determine if the addition of a
maleimide group would inhibit the nNOSr activity. Normalized activities are shown in
Fig. 13B. and Fig. 13C. Both of the two negative control groups maintained about 75% of
initial activity.
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The results confirm that the activity drop observed in locked-down CL5SS was
due to the cross-linking between the FMN with FNA domain. Non-specific maleimide
effects or simple thiol-maleimide modification did not repress nNOSr activity. The
results also confirm the nNOSr is in a conformational equilibrium between an open and a
closed conformation involving FMN domain motion and that the closed conformation is
largely an inactive conformation.
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Fig. 14. Effect of cross-linking on CL5SS. A, steady-state cytochrome c reductase
activity of wild type nNOSr and CL5 under CaM-bound and CaM-free condition; B,
Activity of BMOE reacted CL5SS (■), CL5 (●) and CL5SS-NEM (▲)over time
under CaM bound condition. C. activity of pH 9 or DTT treated CL5SS (■), CL5 (●)
and CL5SS-NEM (▲) over time under CaM bound condition.
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2.3.4 Cross-linker Length and Activity of CL5SS-BMs

The conclusion that the electron transfer in nNOSr is regulated by FMN domain
motion raises another interesting question about how the flexibility of the FMN domain
affects the nNOSr actitivity. In order to examine this relationship, we purchased a series
of bis- maleimide cross-linkers with arm length ranging from 8 to 52 Å and then crosslinked CL5SS with these cross-linkers. Their steady state cytochrome c reductase activity
under both CaM-free and CaM-bounded conditions had been measured. The results are
shown in Fig 15.
The results show that the CL5SS-BMs with longer cross-linker have higher
activity, implying that they support greater electron transfer though nNOSr by enabling
nNOSr to adopt a more open conformation. However, the highest cytochrome c reductase
activity observed under the CaM-bounded condition was still significantly lower than the
activity of wild type nNOSr under the same condition. The low activity observed in
CL5SS-BMs with long cross-linker might due to combined effects of several factors.
First, the length of cross-linker might not reach that required for efficient electron transfer
from FMN domain to cytochrome c. Also, the cross-linker might cause difficulty for
FMN domain to get electrons from FAD due to steric hindrance, similar to the effect of
the R1229E mutation on nNOSr[113]. The mechanism of such inhibitory effect requires
further investigation.
The results in Fig. 15 also show that CL5SS cross-linked by the BMs almost lost
the CaM response. Previous studies imply that CaM binding removes the self-repression
on nNOSr by speeding the conformational transitions of nNOSr from closed
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conformation to open conformation and also by altering the conformation
distribution[100]. The CL5SS-BMs are likely stay in close conformation all the time
regardless of CaM binding because the FMN and FAD domains are cross-linked. So it is
not surprising that CaM has little effect on CL5SS-BMs.
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Fig. 15. Rate of steady-state cytochrome c activity versus cross-linker length.
Activities were measured at room temperature in presence of (■) or in absence of (□)
CaM as described in section 2.2.9. The dot line represents of the activity of CL5SS in
present of CaM and the dash line represents the activity of CL5SS in absence of CaM.
Values represent the mean and standard deviation of at least three independent
measurements.
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2.3.5 NADP+ Binding Affinity Is not Affected by Cross-linking.

It is a common feature for oxidized NOSr enzyme that the nicotinamide ring of
NADP+ interact with the FAD isoalloxazine to form a charge-transfer complex, resulting
in a shift of NOSr absorption spectrum[104]. The difference spectrum of nNOSr before
and after NADP+ binding is obtained by subtracting the spectrum of NADP+ free nNOSr
from NADP+ bound nNOSr[104]. Here we compared the binding of NADP+ in wild type
nNOSr and CL5SS by this spectral shift. The spectral shifted of nNOSr proteins is shown
in Fig. 16A. In this figure, the spectral shift of wild type nNOSr has a crest at 510 nm and
a trough at 453 nm along with some modulation in the range of 400 nm to 700 nm, in
well agreement with a previous report[104]. Similar spectral differences were obtained
for both pH9 treated and DTT treated CL5SS. Their peak height at 510 nm and overall
spectra are very similar with wild type nNOSr. The results show the NADP+ binds in
wild type nNOSr, cross-linked CL5SS or uncross-linked CL5SS in a similar manner,
implying the cross-linking does not alter NADP+ binding. To further study the binding
between nNOSr proteins and NADP+, nNOSr proteins at equal concentration were
titrated with NADP+ and the absorbance increase at 510 nm was plotted versus NADP+
concentration (Fig. 16B). The result shows that both cross-linked and uncross-linked
CL5SS also have similar titration curves, indicating that the cross-linking between FNR
and FMN domains does not change the binding affinity of nNOSr with NADP+.
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Fig. 16. Titration of DTT treated CL5SS and pH 9 treated CL5SS with NADP+.
Panel A, the difference spectra of wild type nNOSr, DTT treated CL5SS and pH 9
treated CL5SS before and after adding NADP+; b, nNOSr proteins titrated by Panel
B, each nNOSr protein (20 µM) was titrated with a NADP+ solution. The difference
between absorbance change at 510 nm and the absorbance change at 457 were
recorded as described in section 2.2.14.
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2.3.6 Flavin Reduction Kinetics

Flavin reduction kinetics study is used to examine the electron transfer through
NOSr, especially the hydride transfer from NADPH to FAD domain and FAD-FMN inter
domain electron transfer[111]. Here we investigated the flavin reduction kinetics of the
CLSS-BMs and wild type nNOSr by rapid mixing a 10-fold molar access of NADPH
with each nNOSr protein in the stopped-flow instrument. The spectral change of DTTtreated CL5SS and CL5SS-BMOE during this flavin reduction process was obtained and
shown in Fig. 17. Their absorbance changes at 457 nm during the flavin reduction were
shown in the insert of Fig. 17. This shows both cross-linked and uncross-linked CL5SS
achieved the same extent of reduction, which is also similar with wild type nNOSr[111].
During our experiment, we observed an absorption increase at 600 nm with a sequential
absorption decrease for both CL5SS-BMOE and DTT treated CL5SS (Fig.18). The
results indicate that flavin semiquinone was first formed then decayed during the flavin
reduction. The fitted semiquinone formation rate (kf) and semiquinone decay rate (kd)
were also shown in Fig. 18. Similar phenomenon has been observed in other nNOS
mutants[116]. In replica experiments, the absorbance change during the NADPH
reduction of CL5SS proteins was monitored at 457 nm to obtain rate constants. The
absorbance decrease at 457 nm represents the initial FAD reduction by NADPH and the
subsequent reduction of FMN by FADH2. The fitted kinetic parameters are listed and
compared in Table I. We also did the two tailed test to compare the flavin reduction rates
of DTT-treated CL5SS, which is primarily in open conformation, and cross-linked
CL5SS. The rates which are statistically significant differed from the rates of DTT-
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treated CLSS were labeled in Table I. The relationship between flavin reduction rates and
cross-linker length was shown in Fig. 19. Flavin reduction traces of CL5SS-BMOE and
DTT-treated CL5SS were normalized and compared in Fig. 20.
Under both CaM-free and CaM-bound states, the flavin reduction of wild type
nNOSr is biphasic, with a fast phase k1 reflecting the electron transfer from NADPH to
FAD, and a slow phase k2 reflecting the inter-flavin electron transfer from FAD to FMN
and further reduction in flavins[111]. CaM binding increases both k1 and k2 of wild type
nNOSr[111]. The kinetic traces at 457 nm for cross-linked CL5SS were also biphasic
with a fast k1 and slow k2, and CaM did not alter either k1 or k2, indicating CL5SS loses
the kinetic repression normally seen in absence of CaM[111]. This is expected results of
mutation of E816 and R1229[113, 114]. The similarity of k1 for both DTT-treated CL5SS
and cross-linked CL5SSS indicates the cross-linking does not negatively affect the
hydride transfer. In the meantime, an increased k2 was observed in cross-linked CL5SS
with relatively shorter linkers. Also the kf and kd of CL5SS-BMOE are faster than the kf
and kd of DTT-treated CL5SS. The results indicate cross-linking favors the inter-flavin
electron transfer in CL5SS. One possibility is that the BMOE connects the FMN and
FAD domain in a conformation that facilitates the inter-flavin electron transfer. This
conformation may be similar to that observed in the crystal structure of wild type nNOSr,
which shows the FAD and FMN are close together in an orientation that could favor
inter-flavin electron transfer[99]. The CL5SS-BMOE may stay in this conformation thus
resulting in a larger k2. Other CL5SS-BMs behave more like uncross-linked CL5SS as the
cross-linker length increases. Together these results show that the cross-linking did not
impair the hydride transfer and facilitates the inter-flavin electron transfer.
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Fig. 17. Spectral change of CL5SS-BMOE and DTT-treated CL5SS.
Panel A, spectral change of CL5SS-BMOE during flavin reduction.
Panel A insert, absorption change of CL5SS-BMOE at 457 nm during
flavin reduction. Panel B, spectral change of DTT treated CL5SS during
flavin reduction. Panel B insert, absorption change of DTT treated
CL5SS at 457 nm during flavin reduction.
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Fig. 19. Flavin reduction rate versus cross-linker length. The dark gray dash line (--)
represents the k1 for DTT-treated CL5SS in presences of CaM. The light gray dash line
(--) represents the k1 for DTT-treated CL5SS in absence of CaM. The dark gray dot
line (···) represents the k2 for DTT-treated CL5SS in presences of CaM. The light gray
dot line (···) represents the k2 for DTT-treated CL5SS in absence of CaM.
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Fig. 20. Normalized kinetic trace of CL5SS-BMOE, DTT
treated CL5SS and wild type nNOSr
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Table I. Kinetic parameters of nNOSr protein flavin reduction. Rates with ** are rates
with p less than 0.01. Rates with * are rates with P less than 0.05 but more than 0.01.

+CaM
Protien

-CaM

k1

k2

k1

k2

s-1

s-1

s-1

s-1

wt nNOSr

80.8 ± 2.2

12.1 ± 0.6

40.3 ± 7.7

3.1 ± 2.7

CL5SS (DTT)

84.9 ± 13.2

21.3 ± 4.2

79.5 ± 14.5

19.9 ± 3.0

CL5SS-BMOE

*101.3 ± 6.4

**34.3 ± 4.1

110.5 ± 0.7

*30.0 ± 11.3

CL5SS-BMB

88.6 ± 4.3

**30.7 ± 4.0

84.8 ± 7.3

*23.6 ± 1.2

CL5SS-BMH

80.0 ± 15.1

*28.7 ± 2.0

81.0 ± 4.5

19.4 ± 1.7

CL5SS-BM(PEG)2

80.6 ± 7.4

**30.7 ± 2.2

83.8 ± 6.0

**30.3 ± 1.3

CL5SS-BM(PEG)3

97.3 ± 7.3

*29.0 ± 2.1

79.1 ± 4.9

*25.8 ± 2.0

CL5SS-BM(PEG)6

95.3 ± 9.0

25.6 ± 3.5

85.3 ± 5.4

23.6 ± 5.2

CL5SS-BM(PEG)11

86.9 ± 7.1

24.3 ± 5.2

76.9 ± 4.1

21.5 ± 3.3

2.3.7 Cross-linking Shifts the Khq Set Point of nNOSr

Reaction with excess cytochrome c is a direct way to study the conformational
Khq setpoints ([open-reactive]/[closed-unreactive]) of fully-reduced nNOSr proteins and
their flavin semiquinone/hydroquinone cycling[99]. In this experiment, the fully-reduced
(four electron reduced by photo reduction), NADPH bound nNOSr is mixed with 5-10
fold molar excess of cytochrome c[109]. Based on our model (Fig. 7.) and previous
kinetic studies, nNOSr exists in active open or closed conformations that are in
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equilibrium. It has been shown that, under this particular experimental setting that the
fully-reduced nNOSr in an open conformation transfers an electron from FMNhq to
cytochrome c with a rate of 225 s-1, making the reaction between the open conformation
and cytochrome c occur within the stopped-flow instrument mixing dead time, and so
cannot be observed in our experiment [109]. In comparison, the model assumes that the
nNOSr in closed conformation is not capable of directly reducing cytochrome c and only
reduce cytochrome c after transforming into an open conformation[109]. This
transformation depends on the conformational opening, which is slow enough to be
observed by our instrument[109]. So, two different species of nNOSr contribute to the
absorbance change within reduction of the first molar equivalent of cytochrome c. The
absorbance change during the dead time, and from that time to the time point that one
equivalent of cytochrome c is reduced, represents the distribution of open versus closed
conformational states, giving an estimation of Khq. Here we reacted excess cytochrome c
with our locked-down CL5SS, DTT treated CL5SS and nNOSr wild type. The
representative traces are shown in Fig. 21. The horizontal dash line represents the
absorption increase for one equivalent of cytochrome c to be reduced. The vertical dash
line represents the time it took to reduce one equivalent of cytochrome c. The solid
horizontal line is the cytochrome c absorption baseline. The relationship between Khq and
cross-linker length is shown in Fig. 22.
In all the nNOSr proteins we observed same initial fast phase (absorbance gain in
the dead time) and a slower linear phase. The activity of nNOSr proteins calculated from
the tangents of the linear phase matches well with their steady state cytochrome c
activity, suggesting a change from pre-steady state electron transfer to steady-state
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electron transfer occurs quickly. This phenomenon has also been observed in other dualflavin enzyme systems[109]. Data in Fig. 21 shows that the tested CL5SS proteins have
different conformational equilibrium setpoints (Khq). The zero time absorbance of
reduced CL5SS-BMOE is very close to the absorbance of cytochrome c itself, showing
NADPH-bound fully-reduced CL5SS-BMOE almost completely remains in the closed
conformation. The time it took for CL5SS-BMOE to reduce one equivalent cytochrome c
is longer than the CaM-free wild type nNOSr, suggesting the BMOE-cross-linking
causing difficulty for FMNhq to donate electrons to cytochrome c. In contrast, the dead
time absorbance change of the DTT-treated CL5SS-BMOE is very close to the
absorbance for reducing one equivalent of cytochrome c, showing that the fully reduced
CL5SS is almost completely open conformation even in the CaM-free state. The time
required to reduce one equivalent cytochrome c is very close to the instrument dead time,
also suggesting DTT treated CL5SS-BMOE stays in open conformation. Interestingly,
CL5SS-BM(PEG)11 has a relatively low cytochrome c activity but a high Khq value, that
indicates more than 60% of CL5SS-BM(PEG)11 is in a reactive open conformation when
fully reduced and bound with NADPH. The extended BM(PEG)11 cross-linker is over 40
angstroms long and it is not surprising that the BM(PEG)11 provides enough space for
cytochrome c to get close enough to the FMN for electron transfer. Also, BM(PEG)11 can
rotate around its C-C and C-O bonds to create conformational diversity. However, the
time it took to reduce one equivalent cytochrome c is still similar with CaM-free wild
type nNOSr. This suggests that the CL5SS-BM(PEG)11 has a lower activity than the wild
type nNOSr. Moreover, and after donating the first electron, CL5SS-BM(PEG)11 may
have difficulty to continue donating electrons to cytochrome c. It is likely that the
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BM(PEG)11 cross-linker inhibits the FMN domain from getting back to FAD to form a
closed structure thus causing a problem for electron transfer in Ksq. This is similar to the
effect of mutation on residue R1229[113]. These data show that the cross-linker may
impair electron transfer by a combined effect of preventing electron transfer from FMN
to cytochrome c, and by preventing FMN domain dynamics and electron transfer.
Data in Fig. 21 and Fig. 22 show that fully-reduced, NADPH-bound CL5SSBMH, CL5SS-BM(PEG)2 and CL5SS-BM(PEG)3 have a percentage of molecules in the
open conformation that increases with cross-linker length. This implies that even in
cross-linked form, the heme in cytochrome c may still get close enough to the FMN for
electron transfer, and the longer cross-linkers allow the heme in cytochrome c to get
closer to the FMN and thus favor electron transfer.
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Fig. 21. Pre-steady-state cytochrome c reduction traces of CL5SS proteins.
Solid horizontal line is the cytochrome c absorption baseline. Dash horizontal
line is the absorbance of reducing 1 equivalent of cytochrome c. Vertical dash
line is the time took to reduce 1 equivalent of cytochrome c. Panel A, pre-steadystate cytochrome c reduction traces of CL5SS-BMOE. Panel B, pre-steady-state
cytochrome c reduction traces of CL5SS-BMB. Panel C, pre-steady-state
cytochrome c reduction traces of CL5SS-BMH. Panel D, pre-steady-state
cytochrome c reduction traces of CL5SS-BM(PEG)2. Panel E, pre-steady-state
cytochrome c reduction traces of CL5SS-BM(PEG)3. Panel F, pre-steady-state
cytochrome c reduction traces of CL5SS-BM(PEG)11. Panel G, pre-steady-state
cytochrome c reduction traces of DTT treated CL5SS.
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Fig. 22. Cross-linker length versus Khq.

2.3.8 Flavin Fluorescence

Intrinsic flavin fluorescence of nNOSr has been observed previously and CaM
binding increases the flavin fluorescence intensity of wild type nNOSr[104, 112]. Here
we utilized the locked-down CL5SS to study the relationship between flavin fluorescence
and conformation. In this experiment, we first induced CaM binding by adding Ca2+ to
sample which contains nNOSr protein and CaM. Then we stripped CaM down from
nNOSr protein by adding excess of EDTA. The flavin fluorescence of CL5SS-BMOE,
DTT-treated CL5SS, pH9 treated CL5SS and wild type nNOSr during the experiment
were monitored as shown in Fig. 23.
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Results show that CL5SS-BMOE and wild type nNOSr have similar fluorescence
intensity in CaM-free state. CaM binding caused an increase of fluorescence intensity of
wild type nNOSr but only caused a small increase of fluorescence intensity of CL5SSBMOE. The fluorescence intensity of the CaM-free DTT-treated CL5SS is similar to the
fluorescence intensity of CaM-bound wild type nNOSr. Also, CaM binding had a small
effect on its fluorescence intensity. Considering that the CL5SS-BMOE is in a closed
conformation, while the DTT-treated CL5SS is primarily in open conformation, it is clear
that conformation has a strong impact on flavin fluorescence, and that CaM binding
changes wild type nNOSr from a closed conformation to an open conformation. In the
CaM-free state, the flavins in wild type nNOSr are buried in the interior of the protein, as
shown in the crystal structure. It is likely that CaM binding favors the FMN domain
release and converts the flavins to an exposed state, resulting in a stronger fluorescence.

2.4 Conclusion

This chapter described our approach to study the structure - function relationship of
nNOSr by locking down domains using cross-linkers of varying length. The engineered lockeddown nNOSr proteins allowed us to study the property of nNOSr in its closed conformation and a
series of partly open conformations. Our results directly support the existence of a conformational
equilibrium of nNOSr between a closed conformation and an open conformation, which is
dynamic and involves FMN domain motion. Our results also show that nNOSr in a closed
conformation has a normal NADP+ binding affinity and hydride transfer rate, and a slightly faster
interflavin transfer rate, but has a impaired electron transfer rate to its substrate and an overall
lowered activity. The flavin fluorescence changes confirmed the conformational behaviors. The
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bismaleimide cross-linkers also proved to be useful tools to study the distance - activity
relationship of FMN domain motion. The locked-down protein can be also applied to study other
conformation-related regulatory elements in NOS including the CT and related residues[101, 103,
116].
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Fig. 23. Flavin fluorescence of nNOSr proteins. The flavin fluorescence of
wild type nNOSr (○), DTT-treated CL5SS (□), pH-9 treated CL5SS (Δ) and
CL5SS-BMOE (◊) were monitored before and after Ca2+ and EDTA as described
in section 2.2.15.
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CHAPTER III
DEVELOPMENT OF AN ASSAY QUANTIFYING NITRIC OXIDE SYNTHASE
ACTIVITY OF BACTERIAL NITRIC OXIDE SYNTHASE AND CELL
CYTOSOL

3.1 Introduction

3.1.1 Significance of NOS Activity Assay
Dedicated NO production by NOS is required for all NO-related functions[22,
37]. Over- or under- production of NO by NOS manifests in numerous human diseases
and changes the bacterial lifespan[25, 40, 44]. The relationship to NO concentration
makes the quantification of NO key for understanding its biological and physiological
processes, and is a mainstay of NOS characterization. NOS activity measurements have
proven invaluable in understanding NOS function, catalysis and regulation[37, 101, 103,
112]. It is also an indispensable tool for NOS inhibitor characterization and selection[117,
118].

.
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3.1.2 Physiological Chemistry of NO

NO is a gaseous radical with very short half-life[119]. The NO produced by NOS
is converted into more stable compounds immediately after being released by NOS[119].
The major downstream products for NO are the nitrite (NO2-) and nitrate (NO3-)[119]. In
buffer or other physiological fluids, NO is almost completely oxidized into nitrite[119].
The stepwise oxidation of NO by O2 is shown below[119].
2NO + O2 → 2NO2 (1)
2NO + 2NO2 → 2N2O3 (2)
2N2O3 + 2H2O → 4NO2− + 4H+ (3)
Although the oxidation of nitrite by oxygen is very slow in buffer[119], the
produced nitrite in blood can be oxidized into more stable nitrate within several
minutes[119]. One possible mechanism is the oxidation by certain oxyhemoproteins (PFe2+O2) such as oxyhemoglobin (oxyHb)[119]. The reactions are shown below:
2P-Fe2+O2 + 3NO2− + 2H+ → 2P-Fe3+ + 3NO3− + H2O (4)
or
4P-Fe2+O2 + 4 NO2− + 4H+ → 4P-Fe3+ + 4 NO3− + O2 + 2H2O (5)
Another proposed mechanism is the direct oxidation of NO into nitrate by
oxyhemoproteins before nitrite formation[119]. In this process, oxyhemoproteins are
converted into methemoproteins[119].
P-Fe2+O2 + NO → P-Fe3+ + NO3− (6)
However, the mechanism of nitrate formation is not entirely clear till now and
requires further investigation.
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Besides being oxidized by oxygen, NO can react with superoxide species to
generate RNS including peroxynitrite (ONOO-) and peroxynitrous acid (ONOOH)[119].
Both peroxynitrite and peroxynitrous are strong oxidants and potentially involved in
several pathological conditions[119]. The reaction was shown below.
O2− + NO → ONOO− + H+ ↔ ONOOH → NO3− + H+ (7)
Moreover, potent nitrating species nitrosoperoxycarbonate anion (ONOOCO2−)
can be produced in a non-enzymatic pathway from NO and O2− in present of
CO2/HCO3−[119]. The reaction is shown below.
NO + O2− → ONOO− + CO2 → ONOOCO2− → NO3− + CO2 (8)

3.1.3 Assays Auantifying NO

Although directly quantification of the short-lived NO is technically difficult,
quantification of the NO deviated compounds listed in section 3.1.2 is practical. Here we
described the most commonly used methods allowing accurate quantification of NO.

3.1.3.1 Detecting the nitrite and nitrate using Griess assay

Griess assay is colorimetric nitrite assay. It is one of the most commonly used
methods to determinate the NO production by quantifying the stable NO derivative nitrite
and nitrate using sulfanilamide and N-alpha-naphthyl-ethylenediamin, which are referred
to as Griess reagents[119]. The Griess reaction is a two-step reaction as shown in Fig.
24[119]. In this reaction, nitrite first reacts with the sulfanilamide to product a diazonium
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ion. This diazonium ion then reacts with the azo dye reagent (N-alpha-naphthylethylenediamin) producing a pink color compound with maximum absorbance at 540 nm,
which is easily detected by UV-Vis spectrum[119]. Pre-reduction step is needed for the
nitrate detection by Greiss assay because nitrate does not react with Griess reagents[119].
Aspergillus nitrate reductase is commonly used to reduce nitrate to nitrite[119].
Importantly, the NADPH in samples requires special attention because this inevitable
component for NOS catalysis is a also strongly inhibits the Griess reaction[119]. Excess
of lactate dehydrogenase (LDH) and pyruvate is commonly used to consume the excess
NADPH in the samples before performing the Gress assay[119]. Potassium ferricyanide
is an alternative of consuming NADPH[119]. Although the nitrite can be quantified
directly using the absorption at 540 nm, a standard nitrite curve it is commonly used for
its quantification[119].
The color product of Greiss reaction can be quantified by not only the UV-Vis
spectrophotometer but also high throughput instrument such as a 96-well plate reader or a
HPLC. Highly automated HPCL instruments, ENO-20 developed by EiCom is
commercially available specially designed for nitrite/nitrate detection[119]. The nitrite
and nitrate are first separated on a reverse phase column. After that the separated nitrate
is reduced into nitrite by a reduction column packed with cadmium and reduced copper
connected with the reverse phase column. These two separated peaks are then mixed with
Greiss reagent and their peak areas are used to accurately quantify the nitrite and nitrate
with a standard curve obtained from nitrite standards[119]. Ideally this system has nM
level detection limit and small matrix effect since contaminations are separated with
nitrite/nitrate by the reverse phase column[119].
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Fig. 24. Scheme of Greiss reaction

3.1.3.2 Fluorometric Assays

In order to detect trace amount of NO derived nitrite in biological samples,
different fluorometric methods have been developed. Here we describe two of the most
commonly used fluorometric assays.

The diaminonaphthalene assay

2,3-diaminonaphthalene (DAN) is an aromatic diamino compound with weak
fluorescence[119]. However, the reaction between DAN and nitrite produces a highly
fluorescent 2,3-naphthotriazole, which can be used directly for nitrite quantification[119].
The produced 2,3-naphthotriazole has very high quantum yield, making the detection
limit of this assay as low as 10-30 nM[119]. Besides the amazing sensitivity, this assay is
very specific since DAN is a very specific reactant for nitrite[119]. Moreover, DAN
reacts fast with nitrite, which makes it a suitable NO indicator[119]. The high sensitivity
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and specificity makes the diaminonaphthalene assay ideal for nitrite detection in
biological samples, which has low nitrite concentration and contains various
contaminants[119].

The Diaminofluoroscein-2 Assay

Similar to DAN, the relatively non-fluorescence compound diaminofluoroscein-2
(DAF-2) can react with nitrite formation a highly fluorescent triazole compound[119].
Different from DAN, the excitation wavelength of the resulting triazole compound
locates in the visible light range, which makes it compatible with in vivo studies[119].
Moreover, this assay can be used to directly quantify the tiazole derivative produced by
NO-derived nitrosation and oxidative nitrosylation in cell[119]. However, the specificity
of DAF-2 is not as desirable as DAN. Previous study show except for nitrite, DAF-2 can
react with nitroxyl and produces triazole compound, resulting a false positive result[119].
The auto fluorescence of DAF-2 also makes this assay unsuitable for low concentration
detection[119]. The properties of DFA-2 limit the performance of this assay.

3.1.3.3 Oxyhemoglobin Assay

Instead of quantifying the NO derived compound such as nitrite and nitrate, the
oxyhemoglobin (oxyHb) assay quantifies the methemoglobin (metHb) production as
shown in equation (6). The oxyHb – metHb conversion can be characterized by an
absorbance increase at 401 nm, which can be monitored directly by UV-Vis
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spectrophotometer[114]. Compare to the Griess assay and the fluorometric assays, this
assay offers advantage to monitor the real-time NO production because hemoglobin does
not interfere NO production by NOS and absorbance change can be monitored in realtime by UV-Vis spectrophotometer[114]. This assay provides unique advantages to study
the steady-state NO production by NOS within several minutes and has been widely used
to study the kinetics of NOS[114].

3.1.4 Special Concerns about Bacterial NO Detection

Several attempts have been made to quantify the NO synthesis activity of bNOS.
These assays, in general, require an external reductase partner for bNOS to facilitates an
electron transfer chain for NO production since most bNOSs do not have a covalently
attached reductase[80, 81, 120-122]. This makes the selection of external reductase
partner the first priority for bNOS assay setup. The first tested reductase partner of bNOS
is the reductase domain of nNOS and it has been showed that the nNOSr is a very poor
electron donor for bNOS[80]. After that, study shows bacterial flavodoxin and flavodoxin
reductase can act together as reductase partner for bsNOS with decent efficiency[120].
More recent studies discovered a more efficient bacterial flavodoxin reductase for bsNOS
NO[117]. Although attempts have been made to identify the bona fide reductase partner
proteins of bNOS, study suggests there is no dedicated reductase partner for bNOS[84].
This also implies each bNOS may have different optimal choice of reductase partner.
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3.1.5 Special Concerns about NO Detection in Live Tissue

Due the complex matrix effect of biological samples, sample preparation is
usually needed before conducting the quantification of the target NO derivatives[119]. It
is extremely important not to artificially create NO derived contaminations during the
sample preparation. Nitrite may metabolize quickly in biological samples including blood
and cell culture by redox active metals such as thiols, resulting in formation of unstable
nitroso/nitrosyl compounds, which will interfere the nitrite quantification[119]. It is
important to preserve the sample integrity when collecting the sample. These unwanted
reductions are commonly inhibited by perfusing sample with NEM and EDTA[119].
NEM blocks the thiols, prevents the formation of nitroso/nitrosyl compounds and EDTA
chelates with metal ions and inhibits the transition metal catalyzed transnitrosation and
degradation of endogenous RSNOs and nitrite[119].
Although these sample preparation methods increase the reliability of test, the
analysis of blood samples can still be tricky. First, blood must be withdraw as rapidly as
possible and be centrifuged immediately to separate red blood cells (RBCs) from the
plasma to prevent hemolysis[119]. The blood withdrawal should take no more than 20
seconds otherwise hypoxia will be render and this will affect the steady state NO
products[119]. Rapid perfusion of NEM/EDTA is required to inhibit the nitrite
metabolism and minimize the hypoxia[119]. Usually the sample needs to be
homogenized within 2 minutes and analyzed immediately afterwards[119]. Reduced
ambient lighting conditions (<15 Lux) is need during sample preparation to minimize the
photolysis of biological NO metabolites[119].
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The analysis of plasma samples can also be problematic because the heparinized
plasma may be precipitated by the acidic Griess reagent, making these samples difficult
to analyze[119]. Addition of anticoagulant such as EDTA/DTPA may prevent this
problem[119]. Also, pre-precipitation of heparin by protamine sulfate will in many cases
allows the direct determination of nitrite in blood sample[119].
Comparing to blood, urinary samples are much easier for analysis due to its
relatively smaller matrix effect[119]. The urine nitrite analysis is also a non-invasively
method to quantify the in vivo NO metabolites level[119]. However, the tested nitrite
level is a reflection the sum of endogenously product nitrite, dietary nitrite and nitrite
produced by bacteria found in the gut[119]. Thus animals should either be fastened
before collecting urine sample[119]. Also, it is import to include antibiotics in to prevent
growth of bacteria in the collecting tubes to minimize the nitrite production by bacteria in
sample[119].

3.1.6 PEGylation of Hb

Methoxypolyethylene glycol 5000 conjugated hemoglobin (MP4 or Hb-PEG) is
initially developed as a vasodilatory hemoglobin based O2 carrier (HBOC) to fit for the
need of transfusion as a replacement of red cells[123]. Studies show Hb-PEG maintains a
high oxygen binding affinity and does not cause apparent arterial blood pressure increase,
which is the major problem of most of HBOCs[123]. Soon after that, the kinetics of NO
association with PEGylated deoxyhemoglobin (deoxyHb-PEG) and NO oxidation by
PEGylated oxyhemoglobin (oxyHb-PEG) have been studied[124]. The results show
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PEGylation on hemoglobin does not altering NO association while slightly slows the NO
oxidation rates, indicating PEGylation does not significantly change the chemistry
property of the heme center in the hemoglobin[124].

3.1.7 Aims

While an assay for the direct quantification of nitric oxide, suitable for high
through-put analysis for both purified proteins and cell cytosol has not yet been reported,
we set out to develop an assay to address the following methodological hurdles: a)
increase coupling of electron transfer from the orthologue flavodoxins to saNOS, b)
improve detection and sensitivity by direct capture of NO produced by purified saNOS or
cell cytosol containing NOS using oxyHb-PEG, and c) reduce assay time and workup
procedures to enable large sample throughput.

3.2 Experiments

3.2.1 Materials

Methoxypolyethylene glycol 5000 maleimide (PEG-MAL5K) was obtained from
Sigma. All other reagents and materials were obtained from Sigma or source previously
elsewhere[120].
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3.2.2 Expression and purification of iNOS, saNOS, FLDR and YkuN

pCWori vector containing both DNA of a wild type rat 65iNOS full length
(AA65-1269) with a His6 tag and rat calmodulin (CaM) were co-transformed into E. coli
stand BL21 (DE3) for overexpression[125]. CaM was co-transformed to prevent full
length iNOS from proteolysis in the CaM binding region[125]. Transformed E. coli cells
were inoculated in 500 mL LB media at 37°C in presence of 100 mg/mL ampicillin and
100 mg/mL chloramphenicol with vigorous shaking (250 rpm) overnight. Eight 2 L
flasks each containing 50 mL of overnight culture, 450 mL TB and the same antibiotics
were used for expression. The cultures were grown at 37 °C with vigorous shaking. 1
mM IPTG and 1 mM -aminolevulinic acid was added to induce iNOSr expression when
OD600 reached 0.8~1.0. Cultures were transferred to room temperature and grown for
another 72 hrs with vigorous shaking (250 rpm). The cells were harvested by centrifuging
at 5000 rpm for 30 min. The cell pellets were resuspended with minimum volume of 40
mM EPPS, 150 mM NaCl, 10% glycerol, pH 7.6 containing protease inhibitors, PMSF
and lysosome. The resuspended cells were sonicated using a Branson digital sonifier on
ice (3 × 35 s bursts on 35% power, interspaced by 1min). All of the following procedures
were done at 4 °C unless indicated specifically. The lysate were centrifuged at 13000 rpm
for 1 hr and the clear supernatant was loaded onto a gravity Ni2+-nitrilotriaceteta (NiNTA) affinity column pre-equilibrated with 40 mM EPPS, 150 mM NaCl, 10% glycerol,
pH 7.6. The column was washed with 200 ml of 40 mM EPPS, 500 mM NaCl, 10%
glycerol, pH 7.6 containing 40 mM imidazole and eluted with 100 ml of 40 mM EPPS,
150 mM NaCl, 10% glycerol, pH 7.6 containing 160 mM imidazole. The eluted protein
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was load onto another 2’5’ ADP sepharose affinity column pre-equilibrated with 40 mM
EPPS, 150 mM NaCl, 10% glycerol, pH 7.6. The column was washed with 200 ml of 40
mM EPPS, 500 mM NaCl, 10% glycerol, pH 7.6 and eluted with 40 ml of 40 mM EPPS,
150 mM NaCl, 10% glycerol, pH 7.6 containing 1 mM NADPH and 3 mM 2’(3’)-AMP.
Eluted full length iNOS was concentrated using a Millipore concentration unit with 50
kD cut off(EMD Millipore, MA) then dialyzed three times against 1 L of 40 mM EPPS,
150 mM NaCl, 10% glycerol, pH 7.6 with 1mM DTT. Concentrated iNOS was aliquoted
and stored in -70°C. iNOS concentration was measured from ferrous-CO complex using
an extinction coefficient of 76 mM-1 cm-1 at 444 nm[120].
saNOS DNA subcloned into pBAD vector from S. aureus chromosome using
NcoI and EcoRI sites was a generous gift from Dr. Ivan Gusarov in New York University
Medical School. Recombined pBAD-saNOS plasmid was transformed into E. coli strain
BL21 (DE3) for protein expression. Transformant E. coli cells carrying pBAD-saNOS
plasimd grew in 4 L of LB under 37°C with vigorous shaking (250 rpm) until OD600
reached 0.6~0.8 then induced with 2.5% arabinose and 1mM δ-aminolevulinic acid
hydrochloride. Cultures were transferred to room temperature and grown for another 20
hrs with vigorous shaking. Cells were harvested by centrifuging at 5000 rpm for 30 min.
Collected cell pellet was resuspended with minimum amount of 40 mM EPPS, 150 mM
NaCl, 10% glycerol, pH 7.6 containing protease inhibitors, PMSF and lysosome. The
resuspended cells were sonicated using a Branson digital sonifier on ice (5 × 35 s bursts
on 35% power, interspaced by 1min). All of the following procedures were done at 4 °C
unless indicated specifically. Disrupted cells were centrifuged at 13000 rpm for 1hr. The
collected clear supernatant was directly loaded on to a gravity Q-sepharose column pre-
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equilibrated with 40 mM EPPS, 150 mM NaCl, 10% glycerol, pH 7.6. The column was
washed with 400 ml of 40 mM EPPS, 150 mM NaCl, 10% glycerol, pH 7.6 and bound
saNOS was eluted with 100 ml of 40 mM EPPS, 1 M NaCl, 10% glycerol, pH 7.6. Eluted
saNOS was concentrated using the Milipore centrifugal filter units with 30 kD cut off
then dialyzed three times against 1 L of 40 mM EPPS, 150 mM NaCl, 10% glycerol, pH
7.6 with 1 mM DTT. saNOS concentration was measured from ferrous-CO complex
using extinction coefficient 76 mM-1 cm-1 at 444nm [120].
B. subtilis flavodoxins (YkuN) subcloned into pET16b vector from B. subtilis
chromosome using NcoI and BamHI sites was a generous gift from Dr. Andrew Munro in
University of Leicester, UK. Recombinant pETYkuN plasmid was transformed into E.
coli BL21(DE3) strain for protein expression and the expressed protein was purified by a
published method with modification[126]. Transformed E. coli cells carrying pETYkuN
plasmid were cultured in 4 L of LB media in presence of 1 mM ampicillin media at 37°C
with vigorous shaking (250 rpm). 0.5 mM IPTG was added to induce YkuN expression
when OD600 reached 1.0. The cultures were grown at 37 °C for another 20 hrs with
vigorous shaking (250 rpm). Cells were harvested by centrifuging at 5000 rpm for 30
min. The collected cell pellets were resuspended with minimum volume of 50 mM TrisHCl, pH 7.2 containing protease inhibitors, PMSF and lysosome. The resuspended cells
were then sonicated using a Branson digital sonifier on ice (5 × 35 s bursts on 35%
power, interspaced by 1min). All of the following procedures were done at 4 °C unless
indicated specifically. The lysates were centrifuged at 13000 rpm for 1 hr and the cleared
blue supernatant was collected. Powdered ammonium sulfate was added slowly to the
supernatant to give a final concentration 1.5 M with gently stirring. The precipitation was
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removed by centrifugation at 13000 rpm for 1 hr and the clear supernatant was loaded
onto a phenyl-sepharose column pre-equilibrated with 50mM Tris-HCl, 1.5 M
ammonium sulfate pH 7.2. A linear gradient (1.5-0.5 M ammonium sulfate in 50mM
Tris-HCl, pH 7.2) was applied on the phenyl-sepharose column to elute bound YkuN.
The fractions with an A280/A461 ratio equal to or less than 10:1 were retained. These
fractions were pooled, concentrated then dialyzed against 50 mM Tris-HCl, pH 7.2 then
loaded on a Q-Sepharose column pre-equilibrated with 50 mM Tris-HCl, pH 7.2. Bound
YkuN was eluted by a liner salt gradient (50-500 mM KCl in 50 mM Tris-HCl, pH 7.2).
Fractions with most intense yellow color were retained, pooled, concentrated using
Milipore centrifugal filter units with 10 kD cut off then dialyzed against 50 mM TrisHCl, pH 7.2 with 1 mM DTT for three times. The concentration of YkuN was measured
using an extinction coefficient of 7.1 mM-1 cm-1[120].
E. coli flavodoxins NADP+ oxidoreductase (FLDR) subcloned into pCL21 vector
using NcoI and BamHI sites was a generous gift from Dr. Simon Daff in University of
Leicester, UK. Recombinant pCLFLDR plasmid was transformed into E. coli
BL21(DE3) strain for protein expression and the expressed protein was purified with a
published method with modification[120]. Transformed E. coli cells carrying
pCL21FLDR plasmid were cultured in 4 L LB media at 37°C with vigorous shaking (250
rpm) and 1 mM ampicillin. 1 mM IPTG was added to induce FLDR expression when
OD600 reached 1.0. The cultures were grown at 37 °C for another 6 hrs with vigorous
shaking (250 rpm). Harvest cells by centrifuging at 5000 rpm for 30 min. The collected
cell pellets were resuspended with minimum amount of ice-cold 10 mM sodium
phosphate, pH 7.5 containing protease inhibitors, PMSF and lysosome. The resuspended
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cells were sonicated on ice using a Branson digital sonifier (5 × 30 s bursts on 35%
power, interspaced by 1min). All of the following procedures were done at 4 °C unless
indicated specifically. The lysate were centrifuged at 13000 rpm for 1 hr and the clear
supernatant was loaded onto a Q-Sepharose column pre-equilibrated with 10 mM sodium
phosphate, pH 7.5. Bound FLDR was eluted by a liner salt gradient (0-1 M NaCl in 10
mM sodium phosphate, pH 7.5). Fractions with most intense yellow color were retained
and pooled then loaded on to an ADP Sepharose column pre-equilibrated with 10 mM
sodium phosphate, 150 mM NaCl, pH 7.5. The bound FLDR was washed with 200 ml of
10 mM sodium phosphate, 150 mM NaCl, pH 7.5 then eluted with 100 ml of 10 mM
sodium phosphate, 500 mM NaCl, pH 7.5. The eluted FLDR was concentrated using
Milipore centrifugal filter units with 10 kD cut off then dialyzed against 1 L of 10 mM
sodium phosphate, pH 7.5 with 1 mM DTT for 3 times. The concentration of FLDR was
measured using an extinction coefficient of 10 mM-1 cm-1[120].

3.2.3 Preparation of E. coli and Macrophage Cell Cytosol

Cell cytosol of E. coli. BL21(DE3) cells expressing iNOS was prepared using the
method described previously[125]. Briefly, 50 ml culture of induced or un-induced E.
coli. BL21(DE3) cells expressing iNOS was harvested by centrifuging at 5000 rpm for 30
min. All of the following procedures were done at 4 °C unless indicated specifically. Cell
pellets were resuspended with minimum amount of 40 mM EPPS, 150 mM NaCl, 10%
glycerol, pH 7.6 containing protease inhibitors, PMSF and lysosome. The resuspended
cells were sonicated on ice using a Branson digital sonifier (5 × 35 s bursts on 35%
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power, interspaced by 1min) then centrifuged at 13000 rpm for 1hr to collect the clear E.
coli cell cytosol. For macrophage cytosol, RAW264.7 (ATCC, Rockville, MD) cells were
cultured as described elsewhere[127]. Cells were induced by adding 25 µg/ml
lipopolysaccharide (LPS) and 10 units/ml of interferon-γ (IFN- γ) followed by 18 hrs
incubation at 37 °C and 5% CO2 humidified incubator. After the induction, cells were
quickly washed with phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10
mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) and lysed by 3 cycles of freeze and thaw in 40
mM EPPS, 150 mM NaCl, 10% glycerol pH 7.6 with protease inhibitors. Soluble
supernatants after centrifuging lysates at 12000 rpm for 20 min at 4 oC were utilized for
the assay. Uninduced macrophage cell cytosol was prepared using the same method.

3.2.4 Conjugation Hemoglobin (Hb) with Polyethylene Glycol (PEG)

Polyethylene glycol conjugated hemoglobin (PEGylated Hb or Hb-PEG) was
prepared with the same method described by Vandegriff and Kluger[123, 128]. The
conjugation process is shown in Fig. 25. Briefly, commercially available native bovine
methemoglobin (metHb) was mixed with 10 equivalents of 2-iminothiolane (IMT) and 20
equivalents of MAL-PEG5K in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) and kept at 4 °C overnight with gently
stirring. Produced PEGylated metHb (metHb-PEG) was isolated by passing the resulting
mixture through Sephadex G-25 PD10 column pre-equilibrated with PBS to eliminate
unreacted IMT and Mal-PEG5K. PEGylated oxyhemoglobin (oxyHb-PEG) was prepared
by adding excess amount of sodium dithionite (DITH) into the Hb-PEG solution then
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passing the product through Sephadex G-25 PD10 gel filtration column pre-equilibrated
with PBS[129]. Oxyhemoglobin (oxyHb) was made from metHb using then same
method.

Fig. 25. PEGylation Scheme of hemoglobin
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3.2.5 Gel-flitration Analysis of PEG-Hb

Hb-PEG and native Hb were analyzed using an analytical size-exclusion column
(Superdex 200. 10 mm × 300 mm) on FLPC instrument (AKTA FPLC, Amersham
Bioscience, NJ) to determine the size of PEG-Hb in buffer (40 mM EPPS, 150 mM NaCl,
10% glycerol pH 7.6). The effluent was monitored at 280 nm.
3.2.6 UV-Vis Analysis of PEG-Hb

UV-Vis spectrum of Hb-PEG and Hb were compared to determine their
spectroscopic similarities. UV-visible spectra of PEG-Hb and Hb from 250 nm to 700 nm
were obtained using a Shimadzu UV-2401 PC UV-Vis spectrophotometer.

3.2.7 Hb Reductase Activity of FLDR, YkuN, E. coli and Macrophage Cell Cytosol

Hb reductase assay quantifies the rate of metHb → oxyHb conversion. Hb
reductase activity of FLDR, YkuN, E. coli and macrophage cell cytosol was examined to
establish whether they could directly reduce metHb or metHb-PEG as a side reaction to
NO formation (Fig. 26). Assay mixtures contained 40 mM EPPS, 250 mM NaCl, 10%
glycerol, pH 7.6, 25 µM metHb or metHb-PEG with 1.5 µM FLDR, 4.5 µM YkuN or 10
µl uninduced E. coli or macrophage cell cytosol. The reactions were initiated by adding
100 µM NADPH and was monitored by following the absorbance at 401 nm by either
UV-Vis spectrophotometer (for YkuN and FLDR) or 96-well plate reader (for cell
cytosol). For plate reader experiments, one positive control reaction was run
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simultaneously on both UV-Vis spectrophotometer and 96-well plate reader to correlate
the slope calculated by 96-well plate reader with rate measured by UV-Vis
spectrophotometer under the exact same experimental conditions. All the experiments
were done at room temperature. An extinction coefficient of 38 mM-1 cm-1 was used to
calculate Hb or Hb-PEG reduction rate for spectrophotometer assay[114]. Experiments
were done in triplicates and results are shown as mean ± standard deviation.

3.2.8 Steady-state NO Synthase Assay of Purified iNOS, E. coli and Macrophage
Cell Cytosol

The use of oxyhemoglobin assay (oxyHb assay) to determine mNOS activity has
been reported previously [26, 30]. In this assay, large access of NADPH and oxyHb are
used to initiate NO production by NOS to create a pseudo-zero order condition in the
beginning of reaction. The produced NO oxidizes oxyHb into metHb resulting in a linear
increase of absorbance at 401 nm in the beginning of reaction. The absorbance at 401 nm
in is record by spectrophotometer along with time and its slope is calculated. The pseudozero order rate constant is calculated by dividing the slope of with an extinction
coefficient of 38 mM-1 cm-1[114]. The steady-state turnover number (kcat) is calculated
by dividing the pseudo-first order rate constant with the concentration of enzyme used in
the assay. In order to study the ability of oxyHb-PEG to support the oxyHb assay, both
oxyHb-PEG and oxyHb were first used the oxyHb-PEG to determine the NO synthase
activity of purified wild type iNOS. NO synthesis reactions containing 1 μM iNOS, 500
μM L-Arg, 4 μM H4B, 0.2 mM DTT, 25 μM oxyHb or oxyHb-PEG, 150 units/ml SOD,
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40 mM EPPS, 150 mM NaCl and 10% glycerol at pH 7.6 in cuvette were initiated by
adding 100 μM NADPH at room temperature. The activity of iNOS in E. coli or
macrophage cell cytosol were also quantified using both oxyHb and oxyHb-PEG as NO
indicator by oxyHb assay with modifications. The assay was done under the same
condition except the reactions were run in 96-well microplate on SpectraMax M2 plate
reader (Molecular Devices, CA) instead of a cuvette. Slopes were obtained by fitting the
initial velocities to linear equation using software SoftMax Pro 5.3. A cuvette reaction
was run simultaneously to correlate the slope calculated by 96-well plate reader with rate
measured by UV-Vis spectrophotometer under the exact same experimental conditions.
Experiments were done at room temperature and performed in triplicate and the results
were shown as mean ± standard deviation.

Fig. 26. Electron transfer scheme in oxyHb assay system. NO is produced in the
catalytic cycle. The oxyHb react with NO in the NO capture cycle. The redox proteins
react with metHb in the futile cycle.
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3.2.9 Steady-state NO Synthase Assay and NADPH Oxidation Assay of saNOS

The ability of FLDR and YkuN as reductase partners has been studied in bsNOS
systems previously[120]. Here we determined the NO synthase activity of saNOS in the
three-component by the oxyHb assay reported previously with modifications[120].
Reactions were run in 96-well microplate on SpectraMax M2 plate reader (Molecular
Devices, CA). Reaction mixtures contained 40 mM EPPS, 250 mM NaCl, 10% glycerol,
various concentration of H4B or H4F, 0.2 mM DTT, 200 µM NOHA or 500 µM Arg, 150
units/ml SOD, 10 µM oxyHb-PEG, 1 µM saNOS, 1.5 µM FLDR and 4.5 µM YkuN.
Reactions were initiated by adding 100 µM NADPH and absorbance at 401 nm was
recorded. Slopes were obtained by fitting the initial velocities to a linear equation using
software SoftMax Pro 5.3. A cuvette reaction was run simultaneously to correlate the
slope obtained by 96-well plate reader with rate measured by UV-Vis spectrophotometer
under the exact same experimental conditions. An extinction coefficient of 38 mM-1 cm-1
was used to calculate NO synthase rate measured by UV-Vis spectrophotometer. NADPH
oxidation assay was described previously [120]. Briefly, reaction mixture containing 1
µM saNOS, 1.5 µM FLDR and 4.5 µM YkuN in cuvette was initiated by adding 100 µM
NADPH at room temperature. The reactions were monitored by following the absorbance
at 340 nm by spectrophotometer. Extinction coefficient of 6.22 mM-1 cm-1 at 340 nm was
utilized to calculate the NADPH oxidation rate. Experiments were performed in triplicate
and the results were shown as mean ± standard deviation.
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3.2.10 Griess Assay Quantifying Nitrite Formation by saNOS and Cell Cytosol

Griess assay was used to quantify the nitrite production by iNOS in E. coli or
macrophage cell cytosol and the results were compared with NO synthase activity
quantified by oxyHb assay using Hb-PEG. Reactions were run in 96-well microplate on
SpectraMax M2 plate reader (Molecular Devices, CA). Reaction mixtures contained 40
mM EPPS, 250 mM NaCl, 10% glycerol, 100 M H4F, 0.2 mM DTT, 500 µM NOHA,
150 units/ml SOD, 1 µM saNOS, 1.5 µM FLDR and 4.5 µM YkuN. The reactions were
initiated by adding 100 µM NADPH at room temperature then run for 10, 20, 30, 40, 50
or 60 mins. Excess of NADPH was consumed by adding a quenching solution contains
10-units/ml lactate dehydrognease and 10 mM sodium pyruvate to stop further nitrite
formation after reaction at these certain time points. Greiss reagent (a water solution
containing 5 g/L sulfanilamide and 0.5 g/L N-(1-Naphthyl)-Ethylenediamine) was added
into all wells immediately after 60 mins. Produced nitrite was quantified according to a
standard curve obtained from standard nitrite solution prepared the same day of
experiment.

3.2.11 Km and Ki Determination

Plate reader oxyHb assay provides an efficient way to study the inhibitor kinetics
for NOS. Here we characterized the Michaelis constant Km of L-Arg and inhibitor
constant (Ki) of L-NG-monomethyl Arginine (L-NMMA) for both saNOS and iNOS.
Briefly, various amount of L-Arg and L-NMMA were added into reaction mixture
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containing either 1 μM iNOS, 150 units/ml SOD 4 μM H4B, 0.2 mM DTT, 25 μM
oxyHb-PEG, 40 mM EPPS, 150 mM NaCl, 10% glycerol or 1 µM saNOS, 1.5 µM
FLDR, 4.5 µM YkuN, 150 units/ml SOD, 100uM H4F, 0.2 mM DTT, 10 µM oxy HbPEG, 40 mM EPPS, 250 mM NaCl, 10% glycerol, pH 7.6 in each well of 96-well micro
plate. Reactions were initiated by adding 100uM NADPH and absorbance at 401 nm was
recorded by 96 well plate-reader. Slopes were obtained by fitting the initial velocities to
linear equation. A cuvette reaction was run simultaneously to compare the performance
of the 96-well plate reader assay under the exact same experimental conditions. An
extinction coefficient of 38 mM-1 cm-1 was used to calculate NO synthase rate measured
by UV-Vis spectrophotometer. Km of L-arg for iNOS and saNOS was calculated by
fitting Lineweaver-Burk plot[130]. Ki of L-NMMA for iNOS and saNOS was calculated
by fitting the following equation based on Michaelis-Menten mechanism for completive
inhibitors:[131]
′
[𝐼]
𝐾𝑚
=
+1
𝐾𝑚 𝐾𝑖

3.3 Results and Discussion

3.3.1 Characterization of Hb-PEG

PEGylataion is a robust way to increase the size of Hb while do not altering its
O2 binding affinity[123]. Here we characterized the Hb-PEG prepared in our own lab by
size exclusion chromatograph, UV-Vis spectrophotometer and kinetic assay.
(i) Molecular weight analysis
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Prepared Hb-PEG was analyzed by FPLC using a gel filtration Superdex 200
column. Hb-PEG eluted as a broad peak spanning molecular weights 79kD to 173kD
with maximum UV absorption corresponding to a molecular weight of 128 kD (Fig. 27).
The molecular weight of native Hb was calculated to be 62 kD using the same method.
These results are in agreement with previous preparations of oxyHb-PEG reported by
Kluger et al[128].

Fig. 27. FPLC chromatography of PEG-Hb

(ii)UV-Vis analysis
The spectrum of production after PEG-MAL5K conjugation Hb-PEG has a Soret
peak at 405 nm and a charge-transfer band at 631 nm, essentially identical to those of
native met-Hb, indicating the direct product is the PEGylated methemoglobin (metHbPEG) as shown in Fig. 28[132]. Reduction with dithionite (DITH) followed by desalting
using a G25-PD10 column produced a red shift of the absorption maxima with well-
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defined bands appearing at 415 nm (Soret), 543 nm and 576 nm (Q-bands) along with
disappearing of band at 613 nm. These spectral features are characteristic of oxyHb,
suggesting such treatment turns metHb-PEG into PEGlyated oxyhemoglobin (oxyHbPEG) and no significant perturbation of the heme center upon PEG binding[132]. The
high similarity of the UV-visible spectra of native Hb and Hb-PEG in terms of absorption
maxima and band intensity demonstrate no alterations of the heme center in either
oxidation state and coordination environment, enabling the use of the same extinction
coefficients for native Hb and Hb-PEG.

Fig. 28. UV-Vis Spectrum of Hb and Hb-PEG

(iii) Measurement of Mammalian iNOS Activity by oxyHb assay with oxyHb-PEG
In order to study the ability of oxyPEG-Hb to support the NO synthase assay, the
activity of murine iNOS was examined using native oxyHb (control) and oxyHb-PEG
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under the same experimental conditions. An extinction coefficient 38 mM-1 cm-1 was
used to calculation iNOS NO synthase activity for both Hb and Hb-PEG groups based on
the results described above. 4 µM H4B and 500 µM L-Arg were used in the assay. The
NO synthase activity of iNOS was 58.5  3.6 min-1 with native oxyHb and 60.8  2.4
min-1 with oxyHb-PEG. This shows that Hb bound to PEG is as proficient as the native
Hb in capturing NO under these experimental conditions. The above results show we
successfully conjugated MAL-PEG5000 with Hb and the oxyHb-PEG is a suitable
substitute of oxyHb as NO indicator in the NO synthase assay.

3.3.2 A Futile Cycle Impairs the NO Detection in oxyHb Assay

The primary goal of this study was setting up an assay to directly quantify NO
synthesis by either purified saNOS or cell cytosols to expand the usage of oxyHb assay
and shorten the assay time. Most bNOS, including saNOS, lacks covalently attached
reductase domain[25]. The identity and function of the reductase protein partners that
drive NO synthesis in bacteria carrying a NOS protein are currently unknown, so external
reductase partner protein is required in order to set up an in vitro assay to quantify the
NO synthase activity of purified bNOS. Previous studies showed that flavoproteins YkuN
and FLDR support NO synthesis by Bacillus subtilis NOS (bsNOS) with decent
efficiency [120]. The high structural similarity between saNOS and bsNOS [87, 133] led
us to hypothesize that the YkuN/FLDR pair could also support NO synthesis by saNOS.
In order to test this hypothesis, we employed two types of assays commonly used to
quantify mammalian NOS: 1) an indirect assay where the oxidation products of NO,
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nitrite and nitrate are determined using the Griess reagent to quantify saNOS activity, or
2) a direct assay that uses oxyHb as a NO probe. The Griess assay is an end point assay
that measures the final concentration of nitrite, the NO oxidation product, in the end of
reaction. The oxyHb assay is a steady-state spectroscopic assay that monitors the
absorbance change at the characterization wavelength of oxyHb-metHb (401nm)
conversion during reaction. It measures the initial NO releasing rate, which can be done
within a short period of time and exhibits greater sensitivity compared to end-product
formation [28]. Our preliminary results show the YkuN/FLDR is capable of transferring
electron to saNOS for NO production, but the produced NO was detectable only using the
low sensitivity Griess assay but not the high sensitivity oxyHb assay (data not shown).
Similarly, the NO synthase activity of cell cytosol determined by oxyHb with oxyHb is
significantly lower activity than the activity determined by Griess assay (data not shown).
This paradox suggests either a defective electron transfer between the reductase to the
heme center in NOS or electron transfer from NO to the heme center in Hb when the
assays were performed in the presence of native oxyHb. Taking in the consideration that
both YkuN and FLDR are part of the electron transfer chain and many redox proteins
exist in cell cytosol, we hypothesized that metHb, which is the NO oxidation product of
oxyHb, could engage in redox cycling with the flavoproteins or other proteins contained
in cell cytosol, derailing electrons from the metHb building up. Here we refer this redox
cycle as futile cycle, as shown in the right part of Fig. 23. Also, NOS expressed by
bacterial and mammalian cells co-exist with a variety of proteins could act as electron
donor in cell cytosol, which potentially reduce metHb.
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In order to test this hypothesis, we quantified the Hb reductase activity with both oxyHb
and oxyHb-PEG. Fig. 29 shows the kinetic traces of metHb and metPEG-Hb reduced by
the FLDR, YkuN, uninduced E. coli or macrophage cell cytosol. The results showed that
FLDR alone reduced metHb with a rate 1.4 min-1. This reduction rate increased to 1.6
min-1 when both FLDR and YkuN were present. YkuN does not have ability to directly
reduce metHb. Uninduced E. coli and macrophage cell cytosol reduced metHb to the rate
of 0.12 µM-1min-1/µl cytosol and 0.35 µM-1min-1/µl cytosol respectively. The results
showed that the apparent incompatibility oxyHb with the saNOS/FLDR/YkuN system
and cell cytosol was caused by this futile side reaction. More importantly, these unwanted
reactions were eliminated by replacement of native oxyHb with oxyHb-PEG.
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Fig. 29. Hb reduction traces. Panel A, Hb reduction traced by FLDR or
YkuN. Panel B, Hb reduction traced by E. coli or macrophage cell cytosol
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3.3.3 PEGylation on Hb Diminished the Futile Cycle

To further investigate the ability of Hb-PEG as NO indicator, we quantified the
NO synthase activity of purified saNOS using both native oxyHb and oxyHb-PEG as NO
indicator. 100 µM H4B, 500 µM Arg and 20 µM oxyHb/oxyHb-PEG were used in the
assay and the assays were run on both UV-Vis spectrophotometer and 96-well plate
reader and their traces were shown in Fig. 30. The saNOS NO synthase activity
quantified with oxyHb-PEG was 1.5 min-1 while no detectable activity was observed with
oxyHb. This result directly proves oxyHb-PEG is a suitable NO indicator in the saNOS
/YkuN/FLDR system. The fact that the saNOS NO synthase rate is similar to the FLDR
reduction rate explains why no net absorbance gain at 401 nm was observed. On the other
hand, the FLDR reduction rate is significant slower than the reported bsNOS NO
synthase activity, explaining why oxyHb is compatible with bsNOS/YkuN/FLDR system.
Macrophage is the primary source producing iNOS in animal and E. coli is a
universal host cell for NOS over-expression and purification[134]. Here we use the
cytosol from these two cell types as examples to compare the ability of oxyHb and
oxyHb-PEG in oxyHb assay for cell cytosol samples as NO indicator. Fig. 31 showed the
kinetic traces of oxyHb and oxyHb-PEG as NO indicator measuring NO synthase activity
of E. coli or macrophage cell cytosol. Nitrite formation rates of the same cytosol samples
were quantified by Greiss assay and the rates were compared with the NO synthase rates
in Table II.
Our Hb reductase activity measurements and NOS activity experiments confirmed
these unidentified redox proteins contained in cell cytosol are capable of accepting
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electrons from NADPH and drive oxyHb into futile cycle by transferring electrons
directly to its heme center, similar to FLDR. PEGylation of Hb also successfully
eliminates this futile cycle with these proteins. The identity of such proteins is unclear
and requires further study. Quantification of NO instead of nitrite provides a more
accurate NOS activity because nitrite is only a fraction of NO oxidation product.
Together, our results confirmed that two electron transfer pathways, a NO
production pathway and a futile pathway, involved in the oxyHb assay. The NO
production pathway results in an absorption increase at 401 nm while a futile pathway
counteracts such absorption increase by reducing metHb back into oxyHb. Importantly,
PEGylation on Hb diminishes the futile pathway, likely by limiting the direct interaction
between hemoglobin and these redox proteins, making it a suitable NO indicator for both
bacterial NOS and cell cytosol NOS activity quantification. The use of Hb-PEG in 96
well plate reader assay sharply shortens the assay time, greatly improved the assay
through-put, making it a suitable way for cell cytosol NO synthase activity quantification
as well. All following NO synthase activity measurements employ oxyHb-PEG as NO
indicator and were done with 96-well plate-reader.
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Fig. 30. saNOS NO production trances using Hb/Hb-PEG. Panel A, NO
production traces monitored on a 96-well plate reader. Panel B, NO
production traces monitored by UV-Vis spectrophotometer.
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Fig. 31. NO production traces of iNOS in cytosol using oxyHb and oxyHb-PEG.
Upper panel, the NO production traces of iNOS in macrophage cytosol. Bottom panel,
the NO production traces of iNOS in E. coli cytosol.
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Table II. Comparison of NO production rates and nitrite formation rate by macrophage
cell cytosol

3.3.4 NO Synthase Activity and NADPH Oxidation Activity of saNOS

The catalytic activity of NO synthesis and NADPH oxidation by saNOS were
assessed under different conditions in order to further study the electron transfer through
saNOS/YkuN/FLDR system. A summary of these kinetic parameters is presented in
Table III. Our results show that saNOS, FLDR and YkuN are all indispensable
component for saNOS NO production, system lacking any of the three shows little NO
production. This shows saNOS needs an external electron donor for catalysis, which is
expected. Reaction lacking saNOS shows little NO production but still maintains
majority of NADPH oxidation, implying FLDR/YkuN act as reductase partner of saNOS
together, which is similar with their function in bsNOS/FLDR/YkuN system reported
previously[120]. Reaction lacking FLDR only has less than 10% NADPH oxidation
activity while reaction lacking YkuN still has ~70%. These indicate electrons first
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transfer from NADPH to FLRD then to FLDR as shown in Fig. 32. However,
measurement of NADPH oxidation rates showed that the flavoprotein partners and
saNOS is largely uncoupled with respect to NO synthesis compared to mammalian NOS,
indicating FLDR/YkuN is not a very efficiently reductase partner for saNOS. This is not
surprising, considering the fact that saNOS, FLDR and YkuN are all separated by solvent
in the assay mixture instead of being covalently attached. Further, the FLDR and YkuN
orthologs of S. aureus may not be the best structural fits to drive NO synthesis.
Uncovering the native reductase partners of saNOS awaits further investigation. The
result also indicates the NO synthesis by saNOS is the rate-limiting step during the
electron transfer in the saNOS/YkuN/FLDR system under the experiment condition.

Fig. 32. Electron transfer in the saNOS/YkuN/FLDR system.
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Table III. Kinetic activities in the saNOS/YkuN/FLDR system

3.3.5 NO Synthase Activity Using Different Substrates and Cofactors

Unlike mammalian NOSs, bacterial NOS can utilize tetrahydrofolate (H4F) to
drive NO synthesis, in addition to H4B [25]. H4F has an identical pterin head with H4B
and an extended aromatic tail, which is not part of H4B (Fig 31). Structural differences in
the pterin binding pocket of mammalian and bacterial NOSs show that the extended
aromatic tail of H4F cannot be accommodated in the mammalian enzymes[25]. This is
generally believed to be the reason why H4F does not support NO synthesis in
mammalian [25]. And interestingly, the bNOS activity quantified using H4B is always
different from the activity quantified using H4F. This fine structural finding make
bacterial NOS as great drug targets to fight infections caused by their pathogenic hosts,
including S. aureus. Arg and NOHA are two substrates that NOSs use to produce NO. In
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order to study the saNOS catalytic features and optimize the assay condition, we
quantified saNOS NO synthase acitivity using different cofactors and substrates. Dose
dependence curves of different cofactor-substrate combinations are shown in Fig. 33.
Our results show the pterin cofactor is an indispensible component for saNOS NO
synthesis. We did not observe any detectable NO production without a pterin cofactor,
indicating pterin involves directly in the saNOS catalysis, which is similar with its effect
in mNOS catatlysis. The results also show H4F was more proficient than H4B in driving
NO synthesis by saNOS. The H4F’s superiority to H4B to support saNOS NO synthesis is
surprising because it is generally believed that smaller cofactor H4B has higher possibility
getting into the binding pocket of saNOS. One possible explanation is that the aromatic
tail of H4F binds to specific structure elements in saNOS and favors electron transfer
from H4F to saNOS to drive substrate oxidation. Even at high concentrations of H4B or
H4F saNOS did not reach its highest activity. This implies that the biopterin cofactor
binds saNOS loosely, which agrees with the prediction from its crystal structure [25,
133]. Overall, the NO production in S. aureus is likely staying at very low level in order
to maintain the homeostasis of bacterial since NO is toxic at higher concentration. Also,
the NO level in bacteria is possibly regulated by the bio-availability of H4F. Of the two
substrates tested, NOHA was 2-fold more effective than L-Arg in supporting NO
synthesis. This is reminiscent of the behavior of mammalian NOSs and suggests that in
saNOS, L-Arg must undergo two cycles of oxidation to produce NO, just as required in
mammalian NO synthesis.
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Fig. 33. Activity of saNOS with different cofactors and substrates.

3.3.6 Km of Arg and Ki of L-MMA

Km of Arg and Ki of L-MMA for iNOS measured by our assay set well agreement
with published values as shown in Fig. 33[118]. The measured Km of Arg for saNOS is
one fold larger than that of iNOS, implying Arg binding pocket on saNOS does not favor
Arg binding as much as iNOS. The smaller size of Arg binding pocket on saNOS than
iNOS may be the cause of this difference. The fact that Ki of L-MMA for saNOS is ~9
fold larger than that of iNOS further proved that the binding Arg binding pocket on
saNOS and iNOS differs. The structure basis for such difference requires more study.
The fact that L-MMA is a better inhibitor for iNOS than saNOS also suggested that
inhibitors designed based on NOS substrate is not like to have good selectivity.
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Fig. 34. Determination of Km of L-Arg and Ki of L-NMMA. Panel A,
Lineweaver-Burk plot determining Km of L-Arg for iNOS. Panel B, LineweaverBurk plot determining Km of L-Arg for saNOS. Panel C, determining Ki of LNMMA for iNOS and saNOS.
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3.4. Conclusions

This is the first study to present a direct measurement of the NO synthesis activity
of S. aureus NOS and the cell cytosols. We developed a rapid, inexpensive 96-well plate
reader assay that employs Hb modified with PEG5000 to optimize electron transfer
toward NO synthesis. This assay utilizes FLDR and YkuN as reductase partners to
saNOS, which have been proven to support NO synthesis in other systems such as
bsNOS. No special component was needed for assay with cell cytosols except that
oxyHb-PEG is used instead of oxyHb. This Hb-PEG based assay allowed us to uncover
unique features of saNOS including the dose-dependence and preference for
tetrahydrofolate over tetrahydrobiopterin, the NO synthesis rates with natural substrates
L-Arg and NOHA. This assay was also used to study the kinetics of well-established
mammalian NOS inhibitor, L-MMA, for both saNOS and iNOS. From a mechanistic
standpoint our assay revealed that saNOS is largely uncoupled, with NADPH oxidation
rates comparable to the NO synthesis pathway. The structural basis of the bias between
tetrahydrofolate over tetrahydrobiopterin for saNOS is still unclear and requires further
investigation. The usage of tetrahydrofolate over tetrahydrobiopterin for saNOS makes it
an outstanding candidate for drug design. On the contrary, the facts that substrate (L-arg)
binds to iNOS and bNOS with similar affinity, and substrate analog (L-NMMA) inhibits
iNOS with higher potency than saNOS, makes L-arg an unsuitable template for selective
inhibitor design. We anticipate that this assay will facilitate the study of 1) NOS
expression and regulation in mammalian or bacterial cell, 2) function of other bacterial
NOSs and 3) screening of potential drugs to target their host pathogenic microorganisms.
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CHAPTER IV
SELECTION OF STAPHYLOCOCCUS AUREUS NITRIC OXIDE SYNTHASE
INHIBITORS

4.1 Introduction

4.1.1 Staphylococcus aureus

Staphylococcus aureus, discovered in 1880 by Dr. Alexander Ogstom, is a Grampositive, catalase-positive and oxidase-negative facultative anaerobe with approximately
1 µm diameter[135]. The cell division of S. aureus takes place simultaneously in different
planes, making them aggregate into grape-like clusters[135]. The golden color observed
in S. aureus colonies is a result of several carotenoids present in its cell cytosol[135].
External supply of nutrients including many amino acids and vitamins B is needed of the
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growth of S. aureus[135]. S. aureus endogenously produces coagulants, which catalyze
the conversion of fibrinogen to fibrin in plasma, causing plasma coagulation[135]. This
feature has been used to distinguish S. aureus with other bacteria in the same genus[135].
Staphylococcus aureus is a widespread and versatile micro-organism[136-138].
Study shows approximately 30% of the healthy individuals are persistently inhabited by
S. aureus in their skin, mucous membrane and particularly in the anterior nares[138].
Although being nonpathogenic sometimes, S. aureus is one of the leading causes of
hospital- and community- acquired bacterial infections[135]. It can cause various level of
infection from mild skin, soft tissue and lower respiratory tracts infections to lethal
pneumonia, bacteremia, osteomyelitis, endocarditis and sepsis[136]. Besides multiple
levels of infection, S. aureus is related with toxin-mediated diseases including toxic
shock syndrome, scalded skin syndrome and staphylococcal foodborne diseases
(SFD)[137]. Hospital patients with health care risk factor are particularly venerable to S.
aureus infections due to their compromised immune system and medical treatments
involving catheter or injections[135]. In the meantime, health individuals are not risky
free since many community-associated S. aureus can infect people without any prime
heath care risky factors[135].
S. aureus is equipped with a great variety of virulence factors that allow it to
invade human self-defending system[135]. It is also capable of developing resistance to
almost all antibiotics[135, 139]. Historically, penicillin is initially developed as
antibiotics to kill S. aureus, but a penicillin resistant S. aureus strain was found two years
after the discovery of penicillin[139]. After that methicillin was used to fight S. aureus
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but methicillin-resistant S. aureus was reported within one year after the discovery of
methicillin[139]. Vancomycin is currently used to treat S. aureus infections and S. aureus
strain with reduced vancomycin susceptibilities has already been reported[139]. These
unique features make S. aureus a major public health threat and one of the most
extensively studied bacteria[139].

4.1.2 saNOS as a Drug Target

S. aureus is a one of the bacterial species that express a nitric oxide synthase
similar protein (saNOS)[133].

It has been confirmed that saNOS is capable of

endogenously utilizing L-Arginine for NO production[25]. Gusarov et al. first found that
the endogenous NO produced by saNOS could directly react with some antibiotics to
detoxify them or induce catalase production to reduce the intracellular oxidative stress
level, protecting saNOS from a wide spectrum of antibiotics[97]. They also showed
short-term exposure of NO to the nos gene knocked-out S. aureus (nos) could protect it
from aminoglycoside toxicity by limiting the aminoglycoside intake[97]. In the
meantime, it has been shown that methicillin-resistant Staphylococcus aureus (MRSA)
becomes more susceptible to oxidative stress and host cathelicidin antimicrobial peptides
(produced in human neutrophil and capable of killing MRSA) after the removal of nos
gene[140].

However,

the

nos

strains

surprisingly

obtained

resistance

to

aminoglycosides, suggesting the relationship between saNOS and its antibiotic resistance
is more complex than the simple protecting effect of NO[140]. Mouse model study
confirmed that MRSA with saNOS mutation is less virulent and has a decreased survival
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rate[140]. These data indicate that saNOS plays an important role in the innate immune
of S. aureus, suggesting saNOS can be a potential drug target[140, 141]. It will be very
valuable to develop specific saNOS inhibitor to decrease the virulence of S. aureus,
making S. aureus vulnerable to human immune system, or making S. aureus more
susceptible to other commonly used antibiotics.

4.1.3. bNOS Inhibitor Development

There are two major issues for saNOS inhibitor design or selection, to which
special attentions need to be paid. The first issue is, by what way(s), we can inhibit
saNOS activity. Although saNOS catalysis is a multiple-step process, inhibitor affecting
the less essential steps is unlikely to be a potent inhibitor. The facts that saNOS does not
have an attached reductase and it is not likely to have a specific reductase partner make it
less practical to inhibit saNOS activity by interrupting electron transfer from the
reductase partner to saNOS. This leaves us almost no other options but directly inhibition
of saNOS[84]. The second issue is how to make inhibitors only specific to saNOS while
not interfering the function of mNOS. NO produced by mNOS involves in several
important biological functions including blood pressure regulation and immune response
thus avoiding inhibition of mNOS is important for saNOS inhibitors design.
Several mNOS inhibitors derived from L-arginine were tested initially in bacterial
NOS system[117]. These inhibitors compete with L-Arg for the NOS binding site, but do
not support NOS catalysis, and thus repress NOS. However, none of these inhibitors
show potent inhibition or any selectivity toward bNOS. The low potency and poor
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selectivity of these L-Arg derivatives are not unexpected since the L-Arg binding pocket
of mNOS and bNOS are similar[25]. Moreover, some of the L-Arg based inhibitors have
several serious in vivo side effects including hypertension and decreased cardio output
and may cause mortality in some cases, making them an less favorable bNOS inhibitor
candidate[142].
Different from blindly selecting inhibitors from current NOS inhibitor library,
designing bNOS inhibitors targeting the unique bNOS structures has been proved to be a
better strategy[143, 144]. Comparing to mNOS, bNOS is unique in the way that bNOS
lacks the N-terminal hook thus has more exposed pterin binding site which can
accommodate the relatively bigger cofactor H4F while mNOS cannot. Structure inhibitor
design targeting the bNOS ptering binding site is attractive since it is possible to design a
selective inhibitor only bind the bNOS. The Poulos group in Northwestern University
designed and synthesized a series of compounds exploiting the unique bsNOS pterin
binding side and evaluated their potential as bsNOS inhibitors[144]. Crystal structures of
inhibitors bounded bsNOS indicate these inhibitors partially accommodate ptern binding
sites and interact with the bsNOS heme, suggesting these inhibitors are selective against
bsNOS[145]. However, the potencies of these inhibitors are generally poor and kinetic
studies show many of them only weakly interact with bsNOS[145]. Although potent and
selective inhibitor is not identified, studies about these compounds provide a structural
framework for designing better bsNOS inhibitors[145].
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4.1.4 DHFR Inhibitors as saNOS Inhibitors

Dihydrofolate reductase (DHFR) is an enzyme that reduces dihydrofolic acid to
tetrahydrofolic acid in a NADPH dependent way[146]. This enzyme plays an important
role in folate biosynthesis and it is essential for the de novo synthesis of purines,
thymidylic acid and several aminio acid[146, 147]. DHFR is a major drug target for
parasitic protozoa including plasmodium[147]. However, barely any clinically used
human DHFR inhibitors including trimethoprim (TMP) and pyrimethamine (PYR) are
effective against the DHFR of Cryptosporidium hominis, which is a class B biodefense
pathogen causing cryptosporidiosis[147]. In order to develop effective and selective
inhibitors for Cryptosporidium hominis DHFR (ChDHFR), Anderson et al. first identified
the structure features of ChDHFR causing the bias against human DHFR inhibitors then
designed and tested a series of trimethoprim derivatives exploiting a unique binding
pocket in ChDHFR[147]. Several of the designed inhibitors are very potent against
ChDHFR while do not significantly affect the human DHFR activity[147-150].
Although original designed as ChDHFR inhibitors, the structural features of these
trimethoprim derivatives made us think about the possibility of using them as bNOS
inhibitors. The 2,4-diaminopyrimidine structure shared by these compounds are
structurally similar with the biopterin ring of H4B and H4F, suggesting this 2,4diaminopyrimidine head may bind to NOS on the pterin binding site. The extended
phenyl group tail on these DHFR inhibitors may not fit the mNOS H4B binding pocket
but possibly fit the binding pocket of bNOS with a binding pattern similar to the unique
bNOS cofactor H4F, providing selectivity against bNOS.
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4.1.5 Aims

While selective inhibitors for saNOS have not yet been reported, we would like to
evaluate several DHFR inhibitors as saNOS inhibitosr. We also would like to find the
relationship between the inhibitor structure and its potency/selectivity as saNOS
inhibitor.

4.2 Experiments

4.2.1 Materials

The tested TMP derived DHFR inhibitors are generous gifts from Dr. Dennis
Wright, University of Connecticut. PEGylated oxyhemoglobin was prepared with method
described in section 3.2.4. All other reagents and materials were obtained from Sigma or
source reported elsewhere [120].

4.2.2 Protein Expression and Purification

saNOS, B. Subtitlis flavodoxin YkuN, E. coli flavodoxin NADP+ oxidoreducase
FLDR and full length rat iNOS were purified with the methods described in section 3.2.7.
iNOS and saNOS concentration were measured from ferrous-CO complex using
extinction coefficient 76 mM-1 cm-1 at 444 nm[120]. FLDR and YkuN concentration were
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measured using an extinction coefficient of 7.1 mM-1 cm-1and 10 mM-1 cm-1
respectively[120].

4.2.3 Hemoglobin Reductase Activity of FLDR and Cytochrome C Reductase
Activity of YkuN

DHFR inhibitors’ effects on FLDR/YkuN enzyme system was measured by
hemoglobin reductase assay and cytochrome c reductase assay shown in Fig 35. Previous
study in section 3.2.7 shows that FLDR could directly reduce hemoglobin. So we
quantified the hemoglobin reductase activity of FLDR in presence of selected DHFR
inhibitors to study the impact of these inhibitors on the electron transfer from FLDR to its
electron accepter. Similarly, YkuN can receive electrons from NADPH directly or FLDR
and reduce cytochrome c as indicated in section 3.3.4. We quantified the cytochrome c
reductase activity of YkuN in presence of selected DHFR inhibitors to study the impact
of these inhibitors on the electron transfer from YkuN to its electron accepter.
The Hb reductase assay was done as described in section 3.2.7 with
modifications. The assay was done on 96-well microplate on SpectraMax M2 plate reader
(Molecular Devices, CA) with each well containing 25 µM metHb and 1 µM of FLDR in
40 mM EPPS, 250 mM NaCl, 10% glycerol, pH 7.6 buffer with 20 µM inhibitors.
Reaction was initiated by 100 µM NADPH and absorbance at 401 nm in each well was
monitored over time. Slopes of the recorded traces were obtained by fitting the initial
velocities to a linear equation using software SoftMax Pro 5.3. A cuvette reaction was run
simultaneously to correlate the slope calculated by 96-well plate reader with rate
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measured by UV-Vis spectrophotometer under the exact same experimental conditions.
An extinction coefficient of 38 mM-1 cm-1 was used to calculate the hemoglobin reduction
rate measured by UV-Vis spectrophotometer. The cytochrome c reductase assay was
done on 96-well microplate on SpectraMax M2 plate reader (Molecular Devices, CA)
with each well containing 4.5 µM YkuN and 50 µM cytochrome c in 40 mM EPPS, 250
mM NaCl, 10% glycerol, pH 7.6 buffer with 20 µM inhibitors. Reaction was initiated by
100 µM NADPH and absorbance at 550nm in each well was monitored along with time.
Slopes of the recorded traces were obtained by fitting the initial velocities to a linear
equation using software SoftMax Pro 5.3. A cuvette reaction was run simultaneously to
correlate the slope calculated by 96-well plate reader with rate measured by UV-Vis
spectrophotometer under the exact same experimental conditions. An extinction
coefficient of 21 mM-1 cm-1 was used to calculate the cytochrome c reduction rate
measured by UV-Vis spectrophotometer. Experiments were done at room temperature
and performed in triplicate and the results were shown as mean ± standard deviation.

Fig. 35. Scheme of Hb reductase activity and YkuN cytochrome c activity
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4.2.4 IC50 Determination and IC50 Index of Selected Inhibitors

The IC50s of selected DHFR inhibitors, TMP and 4-amino-H4B on saNOS was
obtained from the dose dependent curves after inhibitor addition. Origin Lab 8 were used
to fit these curves using a dose dependent equation to calculate the IC50 of inhibitors
[151]. The NO synthase activities of purified saNOS were quantified using the oxyHb
assay described in section 3.2.9. 100 µM H4F and 200 µM NOHA were used in the assay
to achieve desirable saNOS activity.
The IC50 index of selected DHFR inhibitors were obtained by plotted the
concentration of selected inhibitors vs. both saNOS and iNOS NO synthase activity. The
NO synthase activities of purified full length iNOS were quantified using the oxyHb
assay described in section 3.2.8. The IC50 index were plotted using percentage activity
setting the activity in absence of inhibitors as 100%[81].

4.2.5 Determination of Vmax of saNOS, Km of H4F and Ki of Selected Inhibitors

Dose dependence of H4F on saNOS activity in presence of 20µM DHFR
inhibitors was obtained using saNOS NO synthesis assay described in 3.2.8. The Km of
H4F and Vmax were obtained by fitting the dose-dependent curves with Lineweaver-Burk
equation[130]. K’m of H4F in presence of different amounts of UCP121A and
UCP111F26M were obtained with the same method. Competitive inhibition constant Ki
of UCP121A and UCP111F26M for saNOS was calculated by fitting the following
equation based on Michaelis-Menten mechanism for completive inhibitors[118]:
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4.3 Results and Discussion

4.3.1 Structure Comparison of Inhibitors and H4F

The structure and of chosen DHFR inhibitor, common mNOS cofactor H4B,
bNOS cofactor H4F and mNOS inhibitor 4-Amino-(6R)-5,6,7,8-tetrahydro-L-biopterin
dihydrochloride (4-amino-H4B) are listed and compared in Fig. 36.
H4F is an unique bNOS cofactor sharing the same structure with common mNOS
cofactor H4B except that H4F has an extended glutamyl p-amino benzoic acid side chain
(pABA side chain). Although crystal structure of H4F bound saNOS has not yet been
resolved, it is predicted that the 3,4 amino groups of H4F bind to the saNOS heme
carboxylate by hydrogen bond based on the structure of H4F bounded bsNOS (Protein
Data Bank (PDB) code: 1M7Z). This is similar to the interaction between H4B with
iNOS. On the other hand, the crystal structure of H4B bound iNOS (Protein Data Bank
Code (PBD) code: 1NOD) reveals the H4B side chain clashes with the N-terminal hook
of iNOS, implying that the pABA side chain of H4F would not fit the mNOS pterin
binding pocket. Different from iNOS, the pABA side chain of H4F fits the binding
pocked on bsNOS since bsNOS lacks the N-terminal hook. This difference explains why
only the bNOSs are capable of getting electron from H4F[25]. Considering the facts that
(1) H4F shares same biopterin ring with H4F, (2) biopterin is an indispensable part for
NOS catalysis and (3) H4F is a preferred cofactor for saNOS than H4B as shown in
122

section 3.3.5; we predict that the pABA side chain of H4F is helping H4F interacting with
saNOS and it may be the key to create cofactor analogs which can specifically binds
saNOS.
Inspired by this prediction, we found that the DHFR inhibitors based on TMP
template might be good saNOS inhibitor. They do not have any reducing functional
groups thus are not capable of transferring electrons to saNOS. The chosen DHFR
inhibitors are derivatives of TMP and they are made of three different structural
components, a 2,4-diaminopyrimidine head, a triple bond linker and an extended
aromatic tail. The 2,4-diaminopyrimidine head is structurally similar with the pterin ring
of H4F thus potentially allowing these DHFR inhibitors to bind saNOS. The aromatic tail
on DHFR inhibitors is structurally similar the pABA side chain on H4F. It provides steric
hindrance preventing these inhibitors from binding mNOS and potential strengthens the
interaction between these inhibitors and saNOS. These selected DHFR inhibitors differ in
two ways, (1) the R group on 6 position of 2,4-diaminopyrimidine ring (2) the structure
of the aromotic tail. These modifications alter the binding properties of inhibitors and
may result is a potent and specific saNOS inhibitor.
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Fig. 36. Structure of H4B (1), H4F(2), TMP(3), selected DHFR inhibitors(4)
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4.3.2 Effects of DHFR Inhibitor on YkuN and FLDR

The saNOS NO synthesis in the saNOS/YkuN/FLDR system involves several
electron transfer steps as shown in Fig. 35. Before testing the potency of selected
inhibitors, it is essential to figure out if these inhibitors affect the FLDR (step 1) and
YkuN (step 2) used in the assay as reductase partner for saNOS. Here we employed the
Hb reductase assay and cytochrome c reductase assay to study the impact of selected
inhibitors on step 1 and 2. The Hb reductase activity of FLDR and cytochrome c
reductase activity of YkuN were shown in Fig. 37. The results show all selected
inhibitors have negligible effect on YkuN (electron transfer step 2) and FLDR (electron
transfer step 1). Electron transfer from NADPH directly to flavodoxin YkuN without
flavodoxin reductase is generally unfavored thus slow YkuN cytochrome c reduction rate
was observed.

4.3.3 Effects of DHFR Inhibitors on saNOS.

The dose dependent curves of selected DHFR inhibitors and TMP were shown in
Fig. 38 and their IC50 were listed in Table IV. Among the tested inhibitors, UCP121A
and UCP111F26M showed surprisingly high potency while UCP111B showed no effect
on saNOS NO synthesis. Other inhibitors showed potency similar to the parent
compound TMP. The results show that except for UCP111B, all selected DHFR
inhibitors inhibit saNOS activity by directly affecting the saNOS catalysis. The R group
on the 6 position on the 2,4-diaminopyrimidine head does not seem to have determining
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Fig. 37. Effects of inhibitors on FLDR and YkuN. Panel A, the Hb reductase activity of
FLDR in presence of 15 µM inhibitors. Panel B, the cytochrome c reductase activity of
YkuN in presence of 15 µM inhibitors. Panel C, the cytochrome c reductase activity of
YkuN+FLDR in presence of 15 µM inhibitors. The control represents the activities in
absence of inhibitors.
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effect on the inhibition potency. The most potent inhibitors, UCP121A and
UCP111F26M have different R1 and the IC50 of inhibitors with the same R1 differ
significantly. Opposite to the effect to R1, the aromatic tail structure R2 drastically
changes the IC50 of the inhibitors. One unique structure of the most potent inhibitor
UCP111F26M is the two isopropyl groups on its aromatic tail. These two isopropyl arms
may help the inhibitor stays in specific conformation which stabilizes the inhibitorsaNOS complex. The methoxy group on UCP121A may also has similar effect However,
further study is need to elucidate the structure-potency relationship of these TMP based
inhibitors.
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Fig. 38. IC50 determination of selected inhibitors
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Table IV. IC50 of selected inhibitors
Inhibitor

IC50 (µM)

Trimethoprim

N/A

UCP111F26M

4.4 ± 2.1

UCP121A

36 ± 5.5

UCP1007

56 ± 9.7

UCP113D

369 ± 42

UCP1006

N/A

UCP111B

N/A

4.3.4 Selectivity of Tested Inhibitors

NO produced by iNOS in animal is important for the immune response so we
need an inhibitor which can selectively inhibit the saNOS activity while left the iNOS
activity intact. Here we studied the selectivity of the chosen DHFR inhibiters by
comparing their effect on both iNOS and saNOS. The well-known iNOS inhibitor 4amino-H4B was used as a control. Results in Fig. 39A showed iNOS NO synthase
activity remained almost unchanged in present of 15µM DHFR inhibitors, which is 5
times of H4B used in the assay. As comparison, 15µM 4-amino-H4B inhibits almost all
iNOS NO synthase activity. This result implies, the effective concentration for saNOS
(15µM), DHFR inhibitors do not change iNOS NO synthase activity. Moreover, the IC50
index of UCP121A and UCP111F26M were shown in Fig 39B. This proves directly that
the UCP121A and UCP111F26M are highly selective inhibitors for saNOS. The results
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also prove our hypothesis that the aromatic tail on the DHFR inhibitor preventing them
from binding to iNOS. The modification on the tail seems does not change their
selectivity since the tested inhibitors has little effect on the iNOS activity under the
experiment condition.
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Fig. 39. IC50 index determination. Panel A, inhibitor’s effect
on iNOS. Activity of iNOS were measured in presence of 15 µM
inhibitors. The dash line represents the activity of iNOS in
absence of inhibitor. Panel B, IC50 index of UCP111F26M.
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4.3.5 The Selected DHFR Inhibitors Are Competitive Inhibitors for H4F

The inhibitory mechanism of these DHFR inhibitors is another important question
in this study. In order to elucidate their inhibition mechanism, we obtained the doseresponse curves of H4F on saNOS activity in presence of a set amount of DHFR
inhibitors to test if they are competitive inhibitor of H4F since they were designed as H4F
analogs.
The double reciprocal analysis results were shown in Fig. 40. The Calculated
apparent Km. (Km. app) of H4F and Vmax for saNOS were listed in Table V. The Vmax of
saNOS in presence of all tested compound are all very close to Vmax computed from H4F
dose dependent curve without inhibitors. This clearly showed the selected DHFR
inhibitors are competitive inhibitors of H4F. This proves DHFR inhibitors share the same
binding site with H4F. Considering the structure similarity between H4F and DFHR
inhibitors and the fact that the aromatic tail on the DHFR inhibitor alters the Km of
inhibitor, it is implied that both the 2,4-diaminopyrimidine head and the aromatic tail on
DHFR inhibitors interact with saNOS. Thus modification on either part will change its
affinity to saNOS. The Ki of the two most potent inhibitors, UCP111F26M and
UCP121A were obtained by plotting the Km app versus inhibitor concentration used for the
corresponding Km app calculation (Fig. 41.) The small values of Ki for UCP111F26M also
suggests it is a potent inhibitor.
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Fig. 40. Km and Vmax determination using Lineweaver-Burk plot.
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Fig. 41. Ki determinations of UCP111F26M for saNOS
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Table V. Vmax and Km determination of H4F in absence and presence of DHFR inhibitors
Inhibitors

Vmax(min-1)

Km(mM-1min-2)

No inhibitors (H4F only)

9.035056017

0.193892302

UCP111F26M

7.499625019

1.567046648

UCP1007

7.150518413

0.242259564

UCP121A

9.284189026

0.632346115

UCP113D

10.20824826

0.364638628

4.4 Conclusions

Facile inhibition of saNOS catalysis expands our understanding about saNOS and
gives us a reliable way to specifically inhibit saNOS while not interfering with iNOS
activity. These DHFR inhibitors resemble the structure of saNOS cofactor H4F and
specifically interacts with the saNOS and do not interfere other component enzymes used
in assay. These inhibitors compete binding sites with saNOS cofactor H4F thus inhibit
saNOS activity. The inhibition properties of DHFR inhibitors particularly suggested that
H4F competitor development is a feasible away to develop selective saNOS inhibitor.
The Km differences of different inhibitors suggested that R group in the inhibitor tail
provide specificity to the binding site on the saNOS. However, the actual impacts of each
individual functional group on the aromatic tail still needs to be further studied. It will be
interesting to crystallize the DHFR inhibitor bounded saNOS or do point mutations on
these residues to further identify the cofactor binding site or structure feature on saNOS
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causing specific binding between saNOS and DHFR inhibitors. This will further help us
to design more selective and effective saNOS inhibitor. Also, it would be interesting to
test these DHFR inhibitors on other bNOS system to figure out if this is a common
feature for all bacterial NOS.
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CHAPTER V
GENERAL DISCUSSION

5.1 Summary of Data

The data presented in Chapter 2 seeks to understand the electron transfer
mechanism of nNOSr, while the data present in Chapter 3 and 4 seeks to setting up a
robust approach to quantify saNOS activity and using this assay to evaluate the saNOS
inhibitor. The major finds of the works are summarized as follows:
The study about nNOSr reveals the nNOSr electron is regulated conformationally
by FMN domain motion. In electron transfer through nNOSr, FMN shuttles electron from
FAD to its electron accepter. Constraining of the FMN domain motion severally impairs
the electron transfer through nNOSr. FMNhq and FMNsq is also in equilibrium during
the nNOSr electron transfer and this FMNhq/FMNsq equilibrium is related with the
nNOSr conformational opening-closing.
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In another separated research project focusing on bacterial drug selection, we
found the PEGylated hemoglobin is a suitable NO indicator preventing the hemoglobin
going to the futile cycle during oxyhemoglobin assay and can be used directly
quantifying the NO production by cell cytosol. The assay using PEGylated hemoglobin
as NO indicator and YkuN/FLDR as external reductase partner also successfully
quantified the saNOS activity. With the help of this assay, we tested 6 potential saNOS
inhibitors, which structurally similar with H4F and found two of the tested compounds
were very potent against saNOS while do not significantly interrupted iNOS, providing a
good template for future selective saNOS inhibitor design.

5.2 Experimental Limitations

Due the technical difficulties of generating a full length cys-lite NOS, the electron
transfer studies were first done with the reductase domain only using artificial electron
acceptor cytochrome c, leaving a knowledge gap between the conformation equilibrium
of NOSr and the NO synthase activity of NOSoxy. How this conformation equilibrium
affects the NO synthesis, heme reduction and other behaviors of NOSoxy remains
unknown. Although cytochrome c is a good electron acceptor of nNOSr, the faster
electron transfer from nNOSr to cytochrome c made all intermediates, which may be
important in the electron transfer from nNOSr to nNOSoxy invisible and undetectable by
our experimental approaches. Also, we are not able to get a fully cytochrome c reduction
trace by our stopped-flow instrument since we cannot monitor the absorbance change
within the instrument dead time, resulting in an incomplete information and only an
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estimated Khq value. Although the data we extract from stopped-flow experiment is
sufficient to confirm our hypothesis, we still lack the ability to study kinetics faster than
200 s-1.
On the other hand, whether there are better reductase partner for saNOS remains
unknown, leaving the possibility that FLDR/YkuN may not be an optimal reductase
partner of saNOS. The activity of saNOS quantified by our assay is generally slow, it
would be better if we can identify more efficient reductase partner for saNOS, which will
give us a larger window to study the effect of inhibitor on saNOS activity. Also, due to
the security requirements of our lab, currently we are not allowed to conduct experiments
testing these inhibitors with S. aureus. So the real effect of these inhibitors on S. aureus
remains unclear.

5.3 Future Directions

Different facets of the nNOS conformation can be studied using the locked down
version of NOS. One priority is generating a full length cys-lite nNOS to study the impact
of nNOSr conformation on nNOS overall catalysis. Function of other regulatory elements
within the reductase can also be studied using other locked down nNOSr, such as
studying the function of CT using a CT-FMN locked down nNOSr or CT-FNR locked
down nNOSr. Also, this approach can apply to other NOS isoforms and other protein
systems. Single molecule FRED approaches can be used to get more precise information
about distance in our locked down NOS, providing more information which cannot be
obtained by our current kinetic approaches.
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For the saNOS selection, more efficient reductase may be needed for setting up a
better in vitro assay. Flavindoxin and flavindoxin oxidoreductase from other bacteria may
be good candidates. More importantly, test with live S. aureus bacteria is critical for this
study. Study with behaviors of S. aureus in response to inhibitor may lead us to find other
virulence factor of S. aureus or helping us to reveal the mechanism of how S. aureus
develop antibiotics resistance. Last but not least, structure based design of more potent
and selective inhibitor can benefit great this research and also S. aureus related clinical
researches.
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